Acid-tolerant yeast strains for efficient production of succinic acid, methods for their construction and their use

The genetically modified Pichia kudriabzevi yeast strain addresses the inefficiencies of traditional succinic acid production by enhancing key metabolic activities, enabling high-efficiency succinic acid production at low pH with reduced neutralizing agent use.

JP2024543418AActive Publication Date: 2024-11-21TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024527618
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-24
Filing Date
2022-11-24
Publication Date
2024-11-21
Estimated Expiration
2042-11-24

AI Technical Summary

Technical Problem

Traditional methods for producing succinic acid, such as chemical synthesis, face challenges like high energy consumption, pollution, and difficulty in achieving green manufacturing, while biological fermentation methods using yeast strains have issues with slow growth, genetic modification complexity, and high costs due to the need for neutralizing agents.

Method used

A genetically modified acid-resistant yeast strain, Pichia kudriabzevi, is engineered with enhanced activities of NADPH-dependent malate dehydrogenase, fumarate reductase, pyruvate carboxylase, fumarase, and succinate transport proteins, allowing high-efficiency succinic acid production at low pH with reduced neutralizing agent use.

Benefits of technology

The engineered yeast strain achieves efficient succinic acid production at low pH with minimal neutralizing agents, reducing costs and simplifying purification processes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543418000001
    Figure 2024543418000001
  • Figure 2024543418000002
    Figure 2024543418000002
  • Figure 2024543418000003
    Figure 2024543418000003
Patent Text Reader

Abstract

Provided are genetically modified yeast strains for producing succinic acid, having activity or enhanced activity of NADPH-dependent malate dehydrogenase (EC 1.1.1.82), and optionally also having activity or enhanced activity of at least one of: (i) soluble fumarate reductase (EC 4.2.1.2); (ii) pyruvate carboxylase (EC 6.4.1.1); (iii) fumarase (EC 4.2.1.2); and (iv) succinate transport protein, as well as methods for preparing, producing succinic acid therewith, and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of biotechnology, in particular to a novel acid-tolerant yeast strain for efficient production of succinic acid, its construction method and its use. [Background technology]

[0002] Succinic acid, also known as butanedioic acid, is an intermediate in the tricarboxylic acid cycle of living organisms and an important organic chemical raw material (Chae TU, Ahn JH, Ko YS, et al.Metabolic engineering for the production of dicarboxylic acids and diamines[J].Metabolic Engineering,2019). Succinic acid is widely used in industries such as food, chemical, agricultural and pharmaceutical industries.

[0003] The traditional production methods of succinic acid are chemical methods such as paraffin oxidation, hydrogenation of maleic anhydride, and carbonylation of acrylic acid, in which non-renewable petroleum resources are mainly used as starting materials for synthesis. Chemical synthesis methods have disadvantages such as high energy consumption and high pollution, making it difficult to achieve the requirements of green manufacturing. In contrast, biological fermentation methods for producing succinic acid have low pollution, low energy consumption and fixed carbon dioxide, which is more in line with the national sustainable development strategy. The global production of succinic acid by biological methods may reach 600,000 tons in 2020, with a market value of US$539 million (Hyohak Song, Sang Yup Lee.Production of Succinic Acid by Bacterial Fermentation[J].Enzyme and Microbial Technology,2006,39(3):352-361.).

[0004] Currently, there are two main categories of microbial strains for synthesizing succinic acid: one is fungal / yeast strains, mainly including Aspergillus niger, Aspergillus fumigatus, Byssochlamys nivea, Paecilomyces varioti, Saccharomyces cerevisiae, etc.; the other is fungal / yeast strains, mainly including Actinobacillus succinogenes, Anaerobiospirillum succiniciproducens, Mannheimia succiniciproducens, Bacteroides fragilis, etc. These bacteria include strains that can naturally produce succinic acid, such as Bacillus fragilis, and strains that cannot naturally produce succinic acid, such as Corynebacterium glutamicum and Escherichia coli (Ahn JH, Jang YS, Lee S Y.Production of succinic acid by metabolically engineered microorganisms[J].Current Opinion in Biotechnology,2016,42:54-66). Filamentous fungi have problems such as slow growth, difficulty in genetic modification, poor fermentation uniformity, and tendency of mycelium to aggregate. The addition of a significant amount of neutralizing agent is required for the production of succinic acid by bacterial fermentation to maintain the growth of bacterial cells, which increases the cost of isolation and purification and causes potential contamination problems. Yeast has good acid tolerance and can usually grow at pH 3.0, in which case most of the succinic acid exists in the form of free molecules, so the cost of subsequent isolation and purification can be greatly reduced. Summary of the Invention

[0005] In the present invention, highly efficient production of succinic acid is achieved by metabolic engineering modification starting from the acid-tolerant yeast Pichia kudriabzevii CY902 strain (preserved at the Center for General Microorganisms, China General Mold Species Depository Center (CGMCC) under the accession number CGMCC No. 20885) isolated from the epidermis of wild fruits in Yunnan Province. Specifically, the modified strain can realize highly efficient production of succinic acid at low pH in a fermentation mode with no or low addition of neutralizing agents. In one aspect, the present invention provides a genetically modified succinic acid-producing yeast strain having an activity or enhanced activity of NADPH-dependent malate dehydrogenase, and optionally further having at least one activity or enhanced activity of (i) soluble fumarate reductase activity, (ii) pyruvate carboxylase activity, (iii) fumarase activity, and (iv) succinate transport protein activity.

[0006] Preferably, the NDAPH-dependent malate dehydrogenase is derived from a plant, preferably a C4 plant, more preferably from a plant of the family Poaceae, Cyperaceae, Asteraceae, Euphorbiaceae, Chenopodiaceae, Portulacaceae or Amaranthaceae, or from the genus Euglena or Thermobacillus, more preferably from Sorghum bicolor, Zea mays, Saccharum officinarum, Pisum sativum, Cicer arietinum, Spinacia oleracea, Euglena gracilis or Methanothermobacter thermautotrophicus.

[0007] In one embodiment, the genetically modified succinic acid producing yeast strain further has reduced or inactivated activity of pyruvate decarboxylase and / or NAD-dependent glycerol 3-phosphate dehydrogenase.

[0008] In a further aspect, the invention provides a method of constructing a genetically modified succinic acid producing yeast strain comprising conferring or enhancing NADPH-dependent malate dehydrogenase activity in the strain, and optionally further comprising conferring or enhancing at least one of the following activities: (i) soluble fumarate reductase activity, (ii) pyruvate carboxylase (EC 6.4.1.1) activity, (iii) fumarase (EC 4.2.1.2) activity, and (iv) succinate transport protein activity. Preferably, the NDAPH-dependent malate dehydrogenase is derived from a plant, preferably a C4 plant, more preferably from a plant of the family Poaceae, Cyperaceae, Asteraceae, Euphorbiaceae, Chenopodiaceae, Portulacaceae or Amaranthaceae, or from the genus Euglena or Thermobacillus, more preferably from Sorghum bicolor, Zea mays, Saccharum officinarum, Pisum sativum, Schisa aritinum, Spinacia oleracea, Euglena gracilis or Methanothermobacter thermoautotrophicus.

[0009] In one embodiment, the method further comprises attenuating or inactivating pyruvate decarboxylase and / or NAD-dependent glycerol 3-phosphate dehydrogenase in the strain.

[0010] In a further aspect, the present invention provides a method for producing succinic acid, comprising culturing (preferably at pH<3.5, e.g. in the range of pH 1.5 to 3.5, and / or with no or low addition of neutralizing agent) the genetically modified succinic acid-producing yeast strain of the invention and / or the genetically modified succinic acid-producing yeast strain obtained by the method for constructing a genetically modified succinic acid-producing yeast strain according to the invention.

[0011] In a further aspect, the present invention provides the use of the genetically modified succinic acid-producing yeast strain according to the invention and / or the genetically modified succinic acid-producing yeast strain obtained by the method for constructing the genetically modified succinic acid-producing yeast strain according to the invention in the production of succinic acid (preferably at a pH < 3.5, e.g. in the range of pH 1.5 to 3.5 and / or with or without the addition of a neutralizing agent).

[0012] Unless otherwise defined, technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art, e.g., by reference to Singleton et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY 2nd ed., J. Wiley & Sons (New York, NY 1994); Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, Cold Springs Harbor Press (Cold Springs Harbor, NY 1989).

[0013] As used herein, the term "genetically modified" means that a strain artificially modified by biological means has one or more modifications, such as gene deletions, amplifications or mutations, compared to the initial strain before the artificially modified strain, thereby having modified biological properties, such as improved production characteristics. As used herein, the term "initial strain" may be a naturally occurring strain that is genetically modified or a strain that has other genetic modifications.

[0014] As used herein, the term "succinic acid producing yeast strain" refers to a yeast strain that can produce succinic acid under appropriate conditions (e.g., via fermentation) and secrete succinic acid into the extracellular medium. A succinic acid producing yeast strain has a protein that can transport succinic acid out of the cell, so that succinic acid can be secreted out of the cell after it is produced. Suitable succinic acid transport proteins for use with a given yeast strain are known in the art and include, for example, but are not limited to, the dicarboxylate transport protein SpMAE1 of Schizosaccharomyces pombe and the dicarboxylate transport protein AnDCT-02 of Aspergillus niger.

[0015] Succinic acid producing yeasts are known in the art and include, but are not limited to, Zygosaccharomyces, Torulopsis, Candida, Pichia, Rhodotroula, Saccharomyces, Yarrowia, etc. In one embodiment, the succinic acid producing yeast strain is a strain from the genus Pichia, Saccharomyces or Yarrowia. In a preferred embodiment, the succinic acid producing yeast strain is Pichia kudriabzevi (e.g., strain CICC32244), Saccharomyces cerevisiae (e.g., strain BY4742) or Yarrowia lipolytica (e.g., strain Po1g), for example, Pichia kudriabzevi deposited at the China General Microorganisms Depository Center (CGMCC) under deposit number CGMCC No. 20885.

[0016] As used herein, "having activity" refers to having detectable activity compared to a reference (e.g., an initial or wild-type strain) that does not have such activity.

[0017] As used herein, "having enhanced activity" means that the activity is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 250%, at least 300% or more compared to a reference (e.g., an initial strain or a wild-type strain) having said activity.

[0018] The activity of a protein (e.g., an enzyme) may be produced or enhanced by any suitable means known in the art, including, but not limited to, expressing or overexpressing the corresponding gene encoding the protein in a strain (e.g., via a vector such as a plasmid), introducing a mutation that results in an increase in the activity of the protein, etc.

[0019] In some embodiments, in the genetically modified succinic acid producing yeast strain of the present invention, one or more copies of the target gene or its homologous gene can be integrated into the genome (e.g., via homologous recombination), and can optionally be integrated at any locus of the genome, for example, at a locus where one copy of any gene in the genome is replaced by one or more copies of the target gene or its homologous gene (as long as such integration does not significantly adversely affect the growth and production of the strain).Those skilled in the art know how to integrate transgenes and select strains with integrated transgenes.

[0020] As used herein, the term "reduced or inactivated activity..." or "reduced activity or inactivated..." means that the activity is reduced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or more, or even 100%, compared to a reference activity (e.g., the corresponding activity in an initial or wild-type strain).

[0021] The activity of a protein (e.g., an enzyme) may be reduced or inactivated by any suitable means known in the art, including, but not limited to, using a corresponding attenuated or inactivated gene encoding the protein, introducing a mutation that results in reduced activity or inactivation of the protein, using an antagonist or inhibitor of the protein (e.g., an antibody, a ligand, etc.), etc.

[0022] As used herein, the term "weakened or inactivated gene" means that the activity of the gene, e.g., expression level (when used as a protein-coding gene) or regulatory performance (when used as a regulatory element), is reduced or even undetectable by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or more, compared to a reference (e.g., the corresponding gene in the initial or wild-type strain). In the case of a gene encoding a protein such as an enzyme, "weakened or inactivated gene" also encompasses that the activity level of the protein expressed by the gene is reduced, e.g., by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or more, or even 100%, compared to the activity level of the corresponding protein in the initial or wild-type strain.

[0023] In this specification, the reference may be a wild-type microorganism or a microorganism before the desired genetic manipulation (e.g., the initial microorganism used to perform the genetic manipulation to increase gene activity). In this specification, parent microorganism and initial microorganism may be used interchangeably and refer to the microorganism into which the desired genetic manipulation (e.g., enhancing or weakening the activity of a gene or protein) is performed.

[0024] As used herein, malate dehydrogenase (EC 1.1.1.82 (NADPH-dependent)) is encoded by the MDH gene and is involved in the conversion between oxaloacetate and malate. NADPH-dependent malate dehydrogenase contributes to the conversion of oxaloacetate to malate, consuming one molecule of NADPH in this reaction. Commonly used sources of NADPH-dependent malate dehydrogenase include C4 plants (e.g., plants of the families Poaceae, Cyperaceae, Asteraceae, Euphorbiaceae, Chenopodiaceae, Portulacaceae and Amaranthaceae), Euglena and Thermobacillus, such as Sorghum bicolor, Zea mays, Saccharum officinarum, Pisum sativum, Schisa aritinum, Spinacia oleracea, Euglena gracilis or Methanothermobacter thermoautotrophicus. As used herein, "having NADPH-dependent malate dehydrogenase activity or enhanced activity" means that the strain has NADPH-dependent malate dehydrogenase activity or increased NADPH-dependent malate dehydrogenase activity that catalyzes the conversion of oxaloacetate to malate.

[0025] As used herein, soluble fumarate reductase (EC 1.3.1.6) is encoded by the FRD gene. This enzyme is involved in the interconversion between fumarate and succinate and contributes to the conversion of fumarate to succinate. Commonly used sources of soluble fumarate reductase are yeasts and Kinetoplastidae, particularly Saccharomyces cerevisiae, Trypanosoma brucei, Leishmania mexicana, Trypanosoma cruzi, etc. As used herein, "having fumarate reductase activity or enhanced activity" means that the strain has soluble fumarate reductase activity or increased soluble fumarate reductase activity that converts fumarate to succinate.

[0026] As used herein, fumarase (EC 4.2.1.2) is encoded by the FUM gene. This enzyme is involved in the interconversion between fumarate and malate in the cytoplasm and mitochondria, contributing to the conversion of malate to fumarate. Commonly used sources are Actinobacillus succinogenes, Mannheimia succiniciproducens, Escherichia coli, Pichia kudriabzevi, Rhizopus oryzae, etc. One FUM gene, FUM1, is known to be present in Pichia kudriabzevi. As used herein, "having activity or enhanced activity of fumarase" means that the strain has fumarase activity or increased fumarase activity that converts malate to fumarate.

[0027] As used herein, "succinate transport protein" refers to a protein that can transport intracellular succinate out of the cell, including, but not limited to, the SpMAE1 protein of Schizosaccharomyces pombe (Uniprot database search number: P50537), the dicarboxylate transport protein AnDCT-02 of Aspergillus niger (NCBI reference sequence: XP_001398131.1), and the dicarboxylate transport proteins EcDcuB (gene ID: 948641) and EcDcuC (gene ID: 945000) of Escherichia coli. As used herein, "having activity or enhanced activity of a succinate transport protein" means that the strain has activity or increased activity to transport succinate out of the cell.

[0028] As used herein, the dicarboxylate transport protein SpMAE1 protein of Schizosaccharomyces pombe is encoded by the SpMAE1 gene, and the SpMAE1 protein contributes to transporting intracellular dicarboxylates out of the cell. As used herein, "having an activity or enhanced activity of SpMAE1" means that the strain has an activity or increased activity to transport dicarboxylates out of the cell.

[0029] As used herein, pyruvate carboxylase (EC 6.4.1.1) is encoded by the PYC gene. Pyruvate carboxylase is involved in the interconversion between oxaloacetate and pyruvate in the process of gluconeogenesis, and contributes to the conversion of pyruvate and carbon dioxide to oxaloacetate. Commonly used sources of pyruvate carboxylase include fungi, particularly yeast and filamentous fungi, preferably Saccharomyces cerevisiae, Pichia kudriabzevii, Aspergillus oryzae, Kluyveromyces marxianus, and the like. It is known that one PYC gene, namely the PYC1 gene, is present in Pichia kudriabzevii. As used herein, "having pyruvate carboxylase activity or enhanced activity" means that the strain has the activity or increased activity of converting pyruvate to oxaloacetate.

[0030] As used herein, pyruvate decarboxylase (EC 4.1.1.43) is encoded by the PDC gene and is involved in the decarboxylation of pyruvate in the ethanol synthesis pathway. One PDC gene present in Pichia kudryabzevii is known to be the PDC1 gene. As used herein, "reduced or inactivated pyruvate decarboxylase activity" refers to a reduction or loss of pyruvate decarboxylation activity of this enzyme.

[0031] As used herein, NAD-dependent glycerol 3-phosphate dehydrogenase (EC 1.1.1.8) is encoded by the GPD gene and is involved in the interconversion between glycerone phosphate and glycerol 3-phosphate in the glycerol synthesis pathway. One GPD gene, namely the GPD1 gene, is known to be present in Pichia kudria bzevi. As used herein, "reduced or inactivated NAD-dependent glycerol 3-phosphate dehydrogenase" refers to a reduction or loss of activity of this enzyme that catalyzes the interconversion between glycerone phosphate and glycerol 3-phosphate.

[0032] As used herein, orotidine 5'-phosphate decarboxylase (EC 4.1.1.23) is encoded by the URA3 gene and is involved in the decarboxylation of orotidine 5'-phosphate in the process of pyrimidine synthesis. One URA3 gene is known to be present in Pichia kudriabzevii. As used herein, "reduced or inactivated orotidine 5'-phosphate decarboxylase" refers to a reduction or loss of activity of this enzyme that catalyzes orotidine 5'-phosphate decarboxylation.

[0033] As used herein, alcohol dehydrogenase 1 (EC1.1.1.1) is encoded by the ADH1 gene and is involved in the interconversion between acetaldehyde and ethanol in the ethanol synthesis pathway. As used herein, "reduced or inactivated alcohol dehydrogenase 1 activity" refers to the reduction or loss of activity of this enzyme that catalyzes the interconversion between acetaldehyde and ethanol. In one embodiment, the ADH1 gene in the strain is knocked out, for example, by homologous recombination.

[0034] As used herein, monocarboxylate permease (NCBI reference sequence XP_029320775.1) is encoded by the MCH4 gene. As used herein, "reduced or inactivated monocarboxylate permease activity" refers to the reduction or loss of catalytic activity of this enzyme. In one embodiment, the MCH4 gene in the strain is knocked out, for example by homologous recombination.

[0035] As used herein, the JEN2 gene encodes a dicarboxylate transport protein involved in the process of transporting dicarboxylates from the culture medium into the cells. Two JEN2 genes (JEN2-1 (encoding the polypeptide of SEQ ID NO: 14) and JEN2-2 (encoding the polypeptide of SEQ ID NO: 15)) are known to exist in Pichia kudryabzevii. As used herein, "dicarboxylate transport protein with reduced or inactivated activity" refers to a reduction or loss of activity of the cells to transport dicarboxylates from the culture medium into the cells.

[0036] As used herein, "neutralizing agent" refers to a reagent that precipitates succinic acid in the form of calcium succinate from the fermentation system. Materials that can be used as neutralizing agents are known in the art, including, but not limited to, calcium carbonate.

[0037] As used herein, "no or low neutralizing agent addition" refers to an amount of neutralizing agent that is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or more, or even 100% lower than the amount of neutralizing agent known in the art that is added for the fermentative production of succinic acid. For example, the amount of neutralizing agent added in the method of the present invention can be 0 to 30 g / L.

[0038] As used herein, the terms "polypeptide", "amino acid sequence", "peptide" and "protein" may be used interchangeably herein and refer to an amino acid chain of any length that may contain modified amino acids and / or may be interrupted by non-amino acids. The term also encompasses amino acid chains modified by natural or artificial intervention, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a marker moiety.

[0039] As used herein, the terms "gene", "nucleic acid sequence", "polynucleotide" and "nucleotide sequence" may be used interchangeably herein and refer to a nucleotide chain, including DNA and RNA. "Expression of a gene" or "gene expression" refers to the transcription of a DNA region operably linked to an appropriate regulatory region, particularly a promoter, into biologically active RNA and RNA that can be translated into a biologically active protein or peptide.

[0040] As used herein, "degenerate sequence" refers to a nucleotide sequence that encodes the same amino acid sequence as a particular sequence, but has a different nucleotide sequence due to the degeneracy of genetic codons.

[0041] As used herein, the terms "homology", "sequence identity" and the like are used interchangeably herein. Sequence identity may be detected by alignment of the number of identical nucleotide bases between a polynucleotide and a reference polynucleotide, for example, as determined by a standard alignment algorithm program using a default gap penalty established by each supplier. Whether two nucleic acid molecules have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% "identical" nucleotide sequences can be determined by using known computer algorithms such as BLASTN, FASTA, DNAStar and Gap (University of Wisconsin Genetics Computer Group (UWG), Madison, Wisconsin, USA). For example, the percentage identity of nucleic acid molecules can be determined by comparing sequence information using, for example, the GAP computer program (e.g., Needleman et al. J. Mol. Biol. 48:443 (1970), revised by Smith and Waterman (Adv. Appl. Math. 2:482 (1981)). Briefly, the GAP program defines similarity according to the number of aligned similar symbols (i.e., nucleotides) divided by the total number of symbols in the shorter of the two sequences.

[0042] As used herein, the Pk2365 gene encodes a bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase (EC 4.1.3.17 or 4.1.1.112). As used herein, "a bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase with reduced or inactivated activity" refers to a reduction or loss of activity of this enzyme that catalyzes the decarboxylation of oxaloacetate and the aldol condensation of 3-hydroxy-3-methylglutarate.

[0043] In one aspect, the present invention provides a genetically modified succinate-producing yeast strain having an activity or enhanced activity of NADPH-dependent malate dehydrogenase, and optionally further having at least one activity or enhanced activity of (i) soluble fumarate reductase activity, (ii) pyruvate carboxylase activity, (iii) fumarase activity, and (iv) succinate transport protein activity, where the term "at least one" includes any one, two, three, or all four activities selected therefrom.

[0044] In one embodiment, the present invention provides a genetically modified succinic acid producing yeast strain having NADPH-dependent malate dehydrogenase and soluble fumarate reductase activity or enhanced activity.

[0045] In one embodiment, the present invention provides a genetically modified succinic acid producing yeast strain having NADPH-dependent malate dehydrogenase and pyruvate carboxylase activity or enhanced activity.

[0046] In one embodiment, the present invention provides genetically modified succinic acid producing yeast strains having NADPH-dependent malate dehydrogenase and fumarase activity or enhanced activity.

[0047] In one embodiment, the present invention provides a genetically modified succinate-producing yeast strain having activity or enhanced activity of NADPH-dependent malate dehydrogenase and succinate transport protein.

[0048] In one embodiment, the present invention provides a genetically modified succinic acid producing yeast strain having NADPH-dependent malate dehydrogenase, soluble fumarate reductase and pyruvate carboxylase activities or enhanced activities.

[0049] In one embodiment, the present invention provides a genetically modified succinic acid producing yeast strain having NADPH-dependent malate dehydrogenase, soluble fumarate reductase and fumarase activity or enhanced activity.

[0050] In one embodiment, the present invention provides a genetically modified succinate-producing yeast strain having activity or enhanced activity of NADPH-dependent malate dehydrogenase, soluble fumarate reductase and succinate transport protein.

[0051] In one embodiment, the present invention provides genetically modified succinic acid producing yeast strains having NADPH-dependent malate dehydrogenase, pyruvate carboxylase and fumarase activities or enhanced activities.

[0052] In one embodiment, the present invention provides a genetically modified succinic acid producing yeast strain having activity or enhanced activity of NADPH-dependent malate dehydrogenase, pyruvate carboxylase and succinate transport protein.

[0053] In one embodiment, the present invention provides a genetically modified succinic acid producing yeast strain having activity or enhanced activity of NADPH-dependent malate dehydrogenase, fumarase and succinate transport protein.

[0054] In one embodiment, the present invention provides a genetically modified succinic acid producing yeast strain having NADPH-dependent malate dehydrogenase, soluble fumarate reductase, pyruvate carboxylase and fumarase activity or enhanced activity.

[0055] In one embodiment, the present invention provides a genetically modified succinate-producing yeast strain having activity or enhanced activity of NADPH-dependent malate dehydrogenase, soluble fumarate reductase, pyruvate carboxylase and succinate transport protein.

[0056] In one embodiment, the present invention provides a genetically modified succinate-producing yeast strain having activity or enhanced activity of NADPH-dependent malate dehydrogenase, soluble fumarate reductase, fumarase and succinate transport protein.

[0057] In one embodiment, the present invention provides a genetically modified succinic acid producing yeast strain having activity or enhanced activity of NADPH-dependent malate dehydrogenase, pyruvate carboxylase, fumarase and succinate transport protein.

[0058] In one embodiment, the present invention provides a genetically modified succinate-producing yeast strain having activity or enhanced activity of NADPH-dependent malate dehydrogenase, soluble fumarate reductase, pyruvate carboxylase, fumarase and succinate transport protein.

[0059] In one embodiment, having activity or enhanced activity is achieved by expressing or overexpressing the corresponding coding gene in the strain. Thus, in one embodiment, the gene encoding NADPH-dependent malate dehydrogenase is expressed or overexpressed in the genetically modified succinic acid producing yeast strain.

[0060] In one embodiment, the NADPH-dependent malate dehydrogenase is derived from a plant (preferably a C4 plant, more preferably a plant of the families Poaceae, Cyperaceae, Asteraceae, Euphorbiaceae, Chenopodiaceae, Portulacaceae and Amaranthaceae), the genus Euglena or the genus Thermobacillus, preferably from Sorghum bicolor, Zea mays, Saccharum officinarum, Pisum sativum, Schisa aritinum, Spinacia oleracea, Euglena gracilis or Methanothermobacter thermoautotrophicus, more preferably from Sorghum bicolor.

[0061] In one embodiment, the activity of NADPH-dependent malate dehydrogenase is generated or increased by expressing or overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase in a genetically modified succinate-producing yeast strain. Preferably, the MDH gene encoding an NADPH-dependent malate dehydrogenase is preferably derived from a plant, preferably a C4 plant, more preferably from a plant of the Poaceae, Cyperaceae, Asteraceae, Euphorbiaceae, Chenopodiaceae, Portulacaceae or Amaranthaceae family, or from the Euglena or Thermobacillus genus, more preferably from Sorghum bicolor, Zea mays, Saccharum officinarum, Pisum sativum, Schisa aritinum, Spinacia oleracea, Euglena gracilis or Methanothermobacter thermoautotrophicus, more preferably from Sorghum bicolor.

[0062] In one embodiment, the MDH gene encoding an NADPH-dependent malate dehydrogenase comprises a nucleotide sequence encoding an amino acid sequence having the sequence of SEQ ID NO:1 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having NADPH-dependent malate dehydrogenase activity.

[0063] In one embodiment, the MDH gene encoding NADPH-dependent malate dehydrogenase is integrated into the genome of a genetically modified succinic acid-producing yeast (e.g., Pichia kudriabzevii), for example at the Pk2365 locus. The MDH gene encoding NADPH-dependent malate dehydrogenase may be under the control of a suitable promoter (e.g., the promoter of the FBA1 gene (shown in SEQ ID NO: 17)) and / or terminator (e.g., the terminator of the INO1 gene (shown in SEQ ID NO: 18)).

[0064] In a further embodiment, the genetically modified succinic acid producing yeast strain further comprises or has enhanced soluble fumarate reductase. In one embodiment, the soluble fumarate reductase is derived from yeast and Kinetoplastida, including but not limited to Saccharomyces cerevisiae, Trypanosoma brucei, Leishmania mexicana and Trypanosoma cruzi.

[0065] In one embodiment, soluble fumarate reductase activity is generated or increased by expressing or overexpressing a gene encoding a soluble fumarate reductase in the genetically modified succinate producing yeast strain, preferably said gene encoding a soluble fumarate reductase is preferably from a yeast and Kinetoplastida order, such as but not limited to Saccharomyces cerevisiae, Trypanosoma brucei, Leishmania mexicana and Trypanosoma cruzi.

[0066] In one embodiment, the glyoxysome-localization peptide at the 3' end of the soluble fumarate reductase is partially or completely cleaved and is therefore freely present in the cytoplasm.

[0067] In one embodiment, the gene encoding the soluble fumarate reductase comprises a nucleotide sequence encoding an amino acid sequence having any one of SEQ ID NOs: 3 to 5 and degenerate sequences thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having soluble fumarate reductase activity.

[0068] In one embodiment, a gene encoding a soluble fumarate reductase is integrated into the genome of a genetically modified succinic acid producing yeast (e.g., Pichia kudryabzevii), e.g., at the ADH1 locus. The gene encoding a soluble fumarate reductase may be placed under the control of a suitable promoter (e.g., the promoter of the ADH1 gene (as shown in SEQ ID NO:21)) and / or terminator (e.g., the terminator of the ADH1 gene (as shown in SEQ ID NO:22)).

[0069] In a further embodiment, the genetically modified succinate producing yeast strain further has succinate transport protein activity or enhanced succinate transport protein activity.

[0070] In one embodiment, the succinate transport protein is selected from the group consisting of SpMAE1 protein, AnDCT-02 protein, EcDcuB protein and EcDcuC protein.In one embodiment, the succinate transport protein activity is generated or increased by expressing or overexpressing a gene encoding a succinate transport protein, such as SpMAE1 protein, in the genetically modified succinate-producing yeast strain.In one embodiment, the succinate transport protein activity is generated or enhanced by expressing or overexpressing the SpMAE1 gene.

[0071] In one embodiment, the SpMAE1 gene comprises a nucleotide sequence encoding an amino acid having a sequence of SEQ ID NO:2 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto, and having succinate transport protein activity (e.g., from Schizosaccharomyces pombe). Optionally, the SpMAE1 gene is integrated into the genome of a genetically modified succinate-producing yeast strain (e.g., Pichia kudriabzevii), for example, at the MCH4 locus. The SpMAE1 gene may be under the control of a suitable promoter (e.g., the promoter of the TDH3 gene (as shown in SEQ ID NO:19)) and / or terminator (e.g., the terminator of the GAL2 gene (as shown in SEQ ID NO:20)).

[0072] In a further embodiment, the genetically modified succinic acid producing yeast strain further has pyruvate carboxylase activity or has enhanced pyruvate carboxylase activity. Said pyruvate carboxylase activity can be generated or enhanced by expressing or overexpressing a gene encoding pyruvate carboxylase. The pyruvate carboxylase can be derived from a fungus, in particular yeast and filamentous fungus, preferably Saccharomyces cerevisiae, Pichia kudriabzevii, Aspergillus oryzae, Kluyveromyces marxianus, etc. In one embodiment, the gene encoding pyruvate carboxylase can be selected from the group consisting of the PYC gene of Aspergillus oryzae and the PYC1 gene of Pichia kudriabzevii.

[0073] In one embodiment, the pyruvate carboxylase comprises an amino acid sequence encoded by SEQ ID NO: 6 or 7, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having pyruvate carboxylase activity.

[0074] In one embodiment, the gene encoding pyruvate carboxylase comprises a nucleotide sequence encoding amino acids having the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having pyruvate carboxylase activity.

[0075] Optionally, a gene encoding pyruvate carboxylase is integrated into the genome of a genetically modified succinic acid producing yeast (e.g., Pichia kudriabzevii), for example at the JEN2-1 locus. The gene encoding pyruvate carboxylase may be placed under the control of a suitable promoter (e.g., the promoter of the TDH3 gene (shown in SEQ ID NO: 19)) and / or terminator (e.g., the terminator of the GAL2 gene (shown in SEQ ID NO: 20)).

[0076] In further embodiments, the genetically modified succinic acid producing yeast strain further has fumarase activity or has enhanced fumarase activity. Fumarase activity can be generated or enhanced by expressing or overexpressing a gene encoding fumarase. In one embodiment, the genetically modified succinic acid producing yeast strain expresses or overexpresses a gene encoding fumarase. In one embodiment, the fumarase is derived from, for example, but not limited to, Actinobacillus succinogenes, Mannheimia succiniciproducens, Escherichia coli, Pichia kudriabzevi and Rhizopus oryzae.

[0077] In one embodiment, the fumarase comprises the amino acid sequence of SEQ ID NO: 95, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having fumarase activity.

[0078] In one embodiment, the mitochondrial localization peptide at the 5' end of the fumarase is partially or completely truncated and therefore cannot localize to mitochondria but is free to reside in the cytoplasm.

[0079] In one embodiment, the gene encoding fumarase comprises a nucleotide sequence encoding an amino acid sequence having the sequence of SEQ ID NO:8 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having fumarase activity.

[0080] Optionally, the gene encoding fumarase is integrated into the genome of a genetically modified succinic acid producing yeast (e.g., Pichia kudryabzevii), e.g., at the PDC1 locus. The gene encoding fumarase may be placed under the control of a suitable promoter (e.g., the promoter of the TDH3 gene (shown in SEQ ID NO: 19)) and / or terminator (e.g., the terminator of the GAL2 gene (shown in SEQ ID NO: 20)).

[0081] The gene that needs to be expressed or overexpressed can be integrated into the genome at any suitable position, as long as such integration does not adversely affect the growth, proliferation and / or productivity of the strain. For example, the gene that needs to be expressed or overexpressed can be integrated into any one or more positions of the genome that encodes the following proteins: (i) pyruvate decarboxylase (EC 4.1.1.43), (ii) NAD-dependent glycerol 3-phosphate dehydrogenase (EC 1.1.1.8), (iii) orotidine 5'-phosphate decarboxylase (EC 4.1.1.23), (iv) monocarboxylate permease, (v) dicarboxylate transport protein, (vi) alcohol dehydrogenase 1 (EC 1.1.1.1), and (vii) bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase (EC 4.1.3.17 or 4.1.1.112).

[0082] In a further embodiment, the genetically modified succinic acid producing yeast strain further has reduced activity or inactivated at least one of (i) pyruvate decarboxylase (EC 4.1.1.43), (ii) NAD-dependent glycerol 3-phosphate dehydrogenase (EC 1.1.1.8), (iii) orotidine 5'-phosphate decarboxylase (EC 4.1.1.23), (iv) monocarboxylate permease, (v) dicarboxylate transport protein, (vi) alcohol dehydrogenase 1 (EC 1.1.1.1), and (vii) oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase bifunctional enzymes (EC 4.1.3.17 or 4.1.1.112).

[0083] In one embodiment, the genetically modified succinic acid-producing yeast strain has a pyruvate decarboxylase with reduced or inactivated activity. The pyruvate decarboxylase with reduced or inactivated activity can be achieved by weakening or inactivating the gene encoding pyruvate decarboxylase in the strain. Thus, in one embodiment, the genetically modified succinic acid-producing yeast strain has a weakened or inactivated gene encoding pyruvate decarboxylase. In one embodiment, the gene encoding pyruvate decarboxylase in the genetically modified succinic acid-producing yeast strain, such as the PDC1 gene, is knocked out.

[0084] In one embodiment, the pyruvate decarboxylase comprises an amino acid sequence of SEQ ID NO: 10, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having pyruvate decarboxylase activity.

[0085] In one embodiment, the gene encoding pyruvate decarboxylase encodes a protein of SEQ ID NO: 10, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having pyruvate decarboxylase activity.

[0086] In one embodiment, the genetically modified succinic acid producing yeast strain further comprises a reduced or inactivated NAD-dependent glycerol 3-phosphate dehydrogenase. In one embodiment, the genetically modified succinic acid producing yeast strain comprises a weakened or inactivated gene encoding an NAD-dependent glycerol 3-phosphate dehydrogenase. In one embodiment, the gene encoding an NAD-dependent glycerol 3-phosphate dehydrogenase in the genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevii) is knocked out.

[0087] In one embodiment, the NAD-dependent glycerol 3-phosphate dehydrogenase comprises an amino acid sequence of SEQ ID NO: 11, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having NAD-dependent glycerol 3-phosphate dehydrogenase activity.

[0088] In one embodiment, the gene encoding an NAD-dependent glycerol 3-phosphate dehydrogenase encodes, for example, a protein of SEQ ID NO: 10, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having NAD-dependent glycerol 3-phosphate dehydrogenase activity.

[0089] In further embodiments, the genetically modified succinic acid producing yeast strain further comprises reduced or inactivated activity of alcohol dehydrogenase 1. In one embodiment, the genetically modified succinic acid producing yeast strain comprises a weakened or inactivated gene encoding alcohol dehydrogenase 1. In one embodiment, the gene encoding alcohol dehydrogenase 1 in the genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevii) is knocked out.

[0090] In one embodiment, the alcohol dehydrogenase 1 comprises the amino acid sequence of SEQ ID NO: 12, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having alcohol dehydrogenase 1 activity.

[0091] In one embodiment, the gene encoding alcohol dehydrogenase 1 encodes an amino acid sequence having alcohol dehydrogenase 1 activity, e.g., a protein of SEQ ID NO: 12, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto.

[0092] In a further embodiment, the genetically modified succinic acid producing yeast strain further has reduced or inactivated activity of orotidine 5'-phosphate decarboxylase (EC 4.1.1.23), a dicarboxylate transport protein, a bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase, and / or a monocarboxylate permease.

[0093] In a further embodiment, the gene encoding orotidine 5'-phosphate decarboxylase and / or the gene encoding a dicarboxylate transport protein (e.g., a JEN2 gene, e.g., a JEN2-1 gene, a JEN2-2 gene) and / or the gene encoding a monocarboxylate permease and / or the gene encoding the bifunctional enzyme oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase in the genetically modified succinic acid producing yeast strain are knocked out.

[0094] In one embodiment, the genetically modified succinic acid producing yeast strain further comprises a bifunctional enzyme with reduced or inactivated activity of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase. Specifically, the genetically modified succinic acid producing yeast strain comprises a weakened or inactivated gene encoding the bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase. Preferably, the gene encoding the bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase in the genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevii) is knocked out.

[0095] In one embodiment, the oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase bifunctional enzyme comprises the amino acid sequence of SEQ ID NO: 9, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto, and having the activity of an oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase bifunctional enzyme.

[0096] In one embodiment, the gene encoding the bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase encodes a protein of SEQ ID NO:9 or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having the activity of a bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase.

[0097] In one embodiment, the genetically modified succinic acid producing yeast strain further has a reduced or inactivated orotidine 5'-phosphate decarboxylase activity. Specifically, the genetically modified succinic acid producing yeast strain has a weakened or inactivated gene encoding orotidine 5'-phosphate decarboxylase. Preferably, the gene encoding orotidine 5'-phosphate decarboxylase in the genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevii) is knocked out.

[0098] In one embodiment, the orotidine 5'-phosphate decarboxylase comprises an amino acid sequence of SEQ ID NO: 13, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having orotidine 5'-phosphate decarboxylase activity.

[0099] In one embodiment, the gene encoding orotidine 5'-phosphate decarboxylase encodes a protein of SEQ ID NO: 13, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having orotidine 5'-phosphate decarboxylase activity.

[0100] In one embodiment, the genetically modified succinic acid producing yeast strain further has a monocarboxylate permease with reduced or inactivated activity. Specifically, the genetically modified succinic acid producing yeast strain has a weakened or inactivated gene encoding a monocarboxylate permease. Preferably, the gene encoding the monocarboxylate permease in the genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevii) is knocked out.

[0101] In one embodiment, the monocarboxylate permease comprises the amino acid sequence of SEQ ID NO: 16, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having monocarboxylate permease activity.

[0102] In one embodiment, the gene encoding the monocarboxylate permease encodes an amino acid sequence having monocarboxylate permease activity, e.g., a protein of SEQ ID NO: 16, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto.

[0103] In one embodiment, the genetically modified succinic acid producing yeast strain further has a dicarboxylate transport protein with reduced activity or inactivated activity. Specifically, the genetically modified succinic acid producing yeast strain has a weakened or inactivated gene encoding a dicarboxylate transport protein. Preferably, the gene encoding a dicarboxylate transport protein in the genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevi), such as the JEN2-1 or JEN2-2 gene, is knocked out.

[0104] In one embodiment, the dicarboxylate transport protein comprises the amino acid sequence of SEQ ID NO: 14 or 15, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having dicarboxylate transport protein activity.

[0105] In one embodiment, the gene encoding the dicarboxylate transport protein encodes an amino acid sequence, e.g., a protein of SEQ ID NO: 14 or 15, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto, and having dicarboxylate transport protein activity.

[0106] In one embodiment, the present invention provides a genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevi, e.g., strain CY902) having an overexpressed MDH gene encoding an NADPH-dependent malate dehydrogenase, and optionally having an endogenous gene encoding an orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding a bifunctional enzyme, oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase, knocked out. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof.

[0107] In one embodiment, the present invention provides a genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevi, e.g., strain CY902) having an overexpressed MDH gene encoding an NADPH-dependent malate dehydrogenase and an overexpressed gene encoding a soluble fumarate reductase, and optionally an endogenous gene encoding an orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding an alcohol dehydrogenase 1 and / or an endogenous gene encoding a bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase are knocked out. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or said gene encoding a soluble fumarate reductase comprises the sequence of any one of SEQ ID NOs: 3-5 or a degenerate sequence thereof.

[0108] In one embodiment, the present invention provides a genetically modified succinate producing yeast strain (e.g., Pichia kudriabzevi, e.g., strain CY902) having an overexpressed MDH gene encoding an NADPH-dependent malate dehydrogenase and an overexpressed gene encoding a succinate transport protein, e.g., the SpMAE1 gene, and optionally an endogenous gene encoding an orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding a monocarboxylate permease and / or an endogenous gene encoding a bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase is knocked out. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or said gene encoding a succinate transport protein comprises the sequence of SEQ ID NO: 2 or a degenerate sequence thereof.

[0109] In one embodiment, the present invention provides a genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevi, e.g., strain CY902) having an overexpressed MDH gene encoding NADPH-dependent malate dehydrogenase and an overexpressed gene encoding fumarase, and optionally an endogenous gene encoding orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding pyruvate decarboxylase and / or an endogenous gene encoding the bifunctional enzymes oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase are knocked out. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or the gene encoding fumarase comprises the sequence of SEQ ID NO: 8 or a degenerate sequence thereof.

[0110] In one embodiment, the present invention provides a genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevi, e.g., strain CY902) having an overexpressed MDH gene encoding NADPH-dependent malate dehydrogenase and an overexpressed gene encoding pyruvate carboxylase, and optionally an endogenous gene encoding orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding a dicarboxylate transport protein, such as the JEN2-1 or JEN2-2 gene and / or an endogenous gene encoding the bifunctional enzymes oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase, are knocked out. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or said gene encoding pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof.

[0111] In one embodiment, the present invention provides a genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevi, e.g., strain CY902) having an overexpressed MDH gene encoding an NADPH-dependent malate dehydrogenase and a gene encoding a pyruvate carboxylase, in which an endogenous gene encoding a pyruvate decarboxylase and an endogenous gene encoding an NAD-dependent glycerol 3-phosphate dehydrogenase are knocked out, and optionally an endogenous gene encoding an orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding a dicarboxylate transport protein (e.g., JEN2 gene, e.g., JEN2-1 gene, JEN2-2 gene) and / or an endogenous gene encoding a bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase are knocked out. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or said gene encoding a pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof.

[0112] In one embodiment, the present invention provides a genetically modified succinate producing yeast strain (e.g., Pichia kudriabzevii, e.g., strain CY902) having an overexpressed MDH gene encoding an NADPH-dependent malate dehydrogenase, a gene encoding a pyruvate carboxylase, a gene encoding a soluble fumarate reductase and a gene encoding a succinate transport protein, e.g., the SpMAE1 gene, in which an endogenous gene encoding pyruvate decarboxylase and an endogenous gene encoding an NAD-dependent glycerol 3-phosphate dehydrogenase are knocked out, and optionally an endogenous gene encoding orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding a dicarboxylate transport protein (e.g., the JEN2 gene, e.g., the JEN2-1 gene, the JEN2-2 gene) and / or an endogenous gene encoding a bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase and / or an endogenous gene encoding alcohol dehydrogenase 1 and / or an endogenous gene encoding a monocarboxylate permease are knocked out. Preferably, the MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, the gene encoding pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof, the gene encoding soluble fumarate reductase comprises the sequence of any one of SEQ ID NOs: 3 to 5 or a degenerate sequence thereof, or the gene encoding succinate transport protein comprises the sequence of SEQ ID NO: 2 or a degenerate sequence thereof.

[0113] In one embodiment, the invention relates to an endogenous mouse model having an overexpressed MDH gene encoding an NADPH-dependent malate dehydrogenase, a gene encoding a pyruvate carboxylase, a gene encoding a soluble fumarate reductase, a gene encoding a fumarase and a gene encoding a succinate transport protein, e.g., the SpMAE1 gene, in which the endogenous gene encoding pyruvate decarboxylase and the endogenous gene encoding NAD-dependent glycerol 3-phosphate dehydrogenase are knocked out, and optionally the endogenous gene encoding orotidine 5'-phosphate decarboxylase, and / or Alternatively, a genetically modified succinic acid producing yeast strain (e.g., Pichia kudryabzevi, e.g., strain CY902) is provided in which an endogenous gene encoding a dicarboxylate transport protein (e.g., a JEN2 gene, e.g., a JEN2-1 gene, a JEN2-2 gene), and / or an endogenous gene encoding a bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase, and / or an endogenous gene encoding alcohol dehydrogenase 1, and / or an endogenous gene encoding a monocarboxylate permease is knocked out. Preferably, the MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, the gene encoding pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof, the gene encoding soluble fumarate reductase comprises the sequence of any one of SEQ ID NOs: 3 to 5 or a degenerate sequence thereof, the gene encoding fumarase comprises the sequence of SEQ ID NO: 8 or a degenerate sequence thereof, or the gene encoding succinate transport protein comprises the sequence of SEQ ID NO: 2 or a degenerate sequence thereof.

[0114] In one embodiment, the JEN2-1 gene encodes a protein of SEQ ID NO:14, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto, and having dicarboxylate transport protein activity.

[0115] In one embodiment, the JEN2-2 gene encodes a protein of SEQ ID NO: 15, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto, and having dicarboxylate transport protein activity.

[0116] In one embodiment, the present invention provides a genetically modified Pichia kudriabzevi, e.g., strain CY902, having an overexpressed MDH gene encoding an NADPH-dependent malate dehydrogenase, and optionally having an endogenous URA3 gene and / or an endogenous Pk2365 gene knocked out. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof.

[0117] In one embodiment, the present invention provides a genetically modified Pichia kudriabzevi, e.g., strain CY902, having an overexpressed MDH gene encoding an NADPH-dependent malate dehydrogenase and an overexpressed gene encoding a soluble fumarate reductase, and optionally having an endogenous URA3 gene and / or an endogenous ADH1 gene and / or an endogenous Pk2365 gene knocked out. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or said gene encoding a soluble fumarate reductase comprises the sequence of any one of SEQ ID NOs: 3-5 or a degenerate sequence thereof.

[0118] In one embodiment, the present invention provides a genetically modified Pichia kudriabzevi, e.g., strain CY902, having an overexpressed MDH gene encoding an NADPH-dependent malate dehydrogenase and an overexpressed gene encoding a succinate transport protein, e.g., the SpMAE1 gene, and optionally, the endogenous URA3 gene and / or the endogenous MCH4 gene and / or the endogenous Pk2365 gene are knocked out. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate thereof, or said gene encoding a succinate transport protein comprises the sequence of SEQ ID NO: 2 or a degenerate thereof.

[0119] In one embodiment, the present invention provides a genetically modified Pichia kudriabzevi, e.g., strain CY902, having an overexpressed MDH gene encoding an NADPH-dependent malate dehydrogenase and an overexpressed gene encoding a fumarase, and optionally having an endogenous URA3 gene and / or an endogenous PDC1 gene and / or an endogenous Pk2365 gene knocked out. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate thereof, or said gene encoding fumarase comprises the sequence of SEQ ID NO: 8 or a degenerate thereof.

[0120] In one embodiment, the present invention provides a genetically modified Pichia kudriabzevi, e.g., strain CY902, having an overexpressed MDH gene encoding NADPH-dependent malate dehydrogenase and an overexpressed gene encoding pyruvate carboxylase, and optionally an endogenous URA3 gene and / or an endogenous JEN2-1 or JEN2-2 gene and / or an endogenous Pk2365 gene are knocked out. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or said gene encoding pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof.

[0121] In one embodiment, the present invention provides a genetically modified Pichia kudriabzevi, e.g., strain CY902, having an overexpressed MDH gene encoding NADPH-dependent malate dehydrogenase and an overexpressed gene encoding pyruvate carboxylase, in which the endogenous PDC1 and endogenous GPD1 genes are knocked out, and optionally the endogenous URA3 gene, and / or the endogenous JEN2 gene, e.g., the JEN2-1 gene, the JEN2-2 gene, and / or the endogenous Pk2365 gene are knocked out. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or said gene encoding pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof.

[0122] In one embodiment, the present invention provides a genetically modified Pichia kudriabzevi, such as the CY902 strain, having an overexpressed MDH gene encoding an NADPH-dependent malate dehydrogenase, an overexpressed gene encoding pyruvate carboxylase, a gene encoding a soluble fumarate reductase and a gene encoding a succinate transport protein, such as the SpMAE1 gene, and wherein the endogenous PDC1 gene and the endogenous GPD1 gene are knocked out, and optionally, the endogenous URA3 gene and / or the endogenous JEN2 gene, such as the JEN2-1 gene, the JEN2-2 gene and / or the endogenous Pk2365 gene and / or the endogenous ADH1 gene and / or the endogenous MCH4 gene are knocked out. Preferably, the MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, the gene encoding pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof, the gene encoding soluble fumarate reductase comprises the sequence of any one of SEQ ID NOs: 3 to 5 or a degenerate sequence thereof, or the gene encoding succinate transport protein comprises the sequence of SEQ ID NO: 2 or a degenerate sequence thereof.

[0123] In one embodiment, the present invention provides a genetically modified Pichia kudryabzevi, e.g., strain CY902, having enhanced activities of Sorghum bicolor NADPH-dependent malate dehydrogenase, Aspergillus oryzae pyruvate carboxylase, Trypanosoma brucei soluble fumarate reductase, Pichia kudryabzevi fumarase (with its 5'-terminal mitochondrial localization peptide truncated) and succinate transport protein SpMAE1, while eliminating endogenous pyruvate decarboxylase and endogenous NAD-dependent glycerol 3-phosphate dehydrogenase activities. In one embodiment, the present invention provides a genetically modified Pichia kudriabzevi, e.g., strain CY902, having an overexpressed MDH gene encoding an NADPH-dependent malate dehydrogenase, a gene encoding a pyruvate carboxylase, a gene encoding a soluble fumarate reductase, a gene encoding a fumarase and a gene encoding a succinate transport protein, e.g., the SpMAE1 gene, and wherein the endogenous PDC1 gene and the endogenous GPD1 gene are knocked out, and optionally, the endogenous URA3 gene, and / or the endogenous JEN2 gene, e.g., the JEN2-1 gene, the JEN2-2 gene, and / or the endogenous Pk2365 gene and / or the endogenous ADH1 gene, and / or the endogenous MCH4 gene are knocked out. Preferably, the MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or the gene encoding pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof, the gene encoding soluble fumarate reductase comprises the sequence of any one of SEQ ID NOs: 3 to 5 or a degenerate sequence thereof, the gene encoding fumarase comprises the sequence of SEQ ID NO: 8 or a degenerate sequence thereof, or the gene encoding succinate transport protein comprises the sequence of SEQ ID NO: 2 or a degenerate sequence thereof.

[0124] In a further aspect, the invention provides a method of constructing a genetically modified succinic acid producing yeast strain comprising conferring NADPH-dependent malate dehydrogenase (EC 1.1.1.82) activity to the strain or enhancing NADPH-dependent malate dehydrogenase (EC 1.1.1.82) activity in the strain.

[0125] As used herein, "conferring an activity" refers to producing an activity in the genetically modified succinic acid-producing yeast strain that was not present in the initial strain prior to the genetic modification.

[0126] As used herein, "enhancing the...activity" refers to, for example, increasing activity by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 250%, at least 300% or more.

[0127] There are many methods known in the art for conferring or enhancing a desired protein activity, including, but not limited to, expressing or overexpressing the protein-encoding gene and mutations or any other modifications that increase the protein activity.

[0128] As used herein, "overexpression" means that the gene expression level is increased compared to the level before genetic manipulation, for example, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 250%, at least 300% or more. Methods for overexpressing genes are well known in the art, including, but not limited to, using strong promoters, increasing gene copy number, enhancers, etc. Increasing gene copy number can be achieved, for example, by introducing one or more copies of an exogenous or endogenous gene, for example, by integration into an expression vector or genome.

[0129] As used herein, "exogenous gene" refers to a gene from another cell or organism, e.g., from the same species or a different species.

[0130] As used herein, "endogenous gene" refers to a gene that originates from the cell or organism itself.

[0131] The promoter may be selected from any suitable promoter known in the art, including, but not limited to, for example, the promoter of the FBA1 gene encoding fructose 1,6-bisphosphate aldolase, the promoter of the TDH3 gene encoding glyceraldehyde 3-phosphate dehydrogenase, the promoter of the PDC1 gene encoding pyruvate decarboxylase, the promoter of the ADH1 gene encoding alcohol dehydrogenase 1, the promoter of the PGK1 gene encoding 3-phosphoglycerate kinase, the promoter of the TEF1 gene encoding transcription elongation factor, the promoter of the GPM1 gene encoding phosphoglycerate mutase, the promoter of the TPI1 gene encoding triosephosphate isomerase, and the promoter of the ENO1 gene encoding enolase (shown in SEQ ID NO: 100).

[0132] In one embodiment, the NADPH-dependent malate dehydrogenase is derived from a plant, preferably a C4 plant, more preferably from a plant of the family Poaceae, Cyperaceae, Asteraceae, Euphorbiaceae, Chenopodiaceae, Portulacaceae and Amaranthaceae, or from the genus Euglena or Thermobacillus, more preferably from Sorghum bicolor, Zea mays, Saccharum officinarum, Pisum sativum, Schisa aritinum, Spinacia oleracea, Euglena gracilis or Methanothermobacter thermoautotrophicus, more preferably from Sorghum bicolor.

[0133] In one embodiment, the NADPH-dependent malate dehydrogenase activity is generated or increased by expressing or overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase in the genetically modified succinate-producing yeast strain. Preferably, said MDH gene encoding an NADPH-dependent malate dehydrogenase is derived from a plant, preferably a C4 plant, more preferably from the family Poaceae, Cyperaceae, Asteraceae, Euphorbiaceae, Chenopodiaceae, Portulacaceae and Amaranthaceae, or from the genera Euglena and Thermobacillus, more preferably from Sorghum bicolor, Zea mays, Saccharum officinarum, Pisum sativum, Schisa aritinum, Spinacia oleracea, Euglena gracilis or Methanothermobacter thermoautotrophicus, more preferably from Sorghum bicolor.

[0134] In one embodiment, the MDH gene encoding an NADPH-dependent malate dehydrogenase comprises a nucleotide sequence encoding an amino acid sequence having the sequence of SEQ ID NO:1 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having NADPH-dependent malate dehydrogenase activity.

[0135] In one embodiment, the MDH gene encoding NADPH-dependent malate dehydrogenase is integrated into the genome of a genetically modified succinic acid producing yeast (e.g., Pichia kudriabzevii), e.g., at the Pk2365 locus. In one embodiment, the MDH gene encoding NADPH-dependent malate dehydrogenase is integrated into the genome of a yeast (e.g., Pichia kudriabzevii), e.g., at the Pk2365 locus, via homologous recombination. The MDH gene encoding NADPH-dependent malate dehydrogenase may be under the control of a suitable promoter (e.g., the promoter of the FBA1 gene (as shown in SEQ ID NO: 17)) and / or terminator (e.g., the terminator of the INO1 gene (as shown in SEQ ID NO: 18)).

[0136] In a further embodiment, the method further comprises conferring soluble fumarate reductase activity to the strain or enhancing soluble fumarate reductase activity in the strain.

[0137] In one embodiment, the soluble fumarate reductase is derived from yeast and Kinetoplastida, including but not limited to Saccharomyces cerevisiae, Trypanosoma brucei, Leishmania mexicana, and Trypanosoma cruzi.

[0138] In one embodiment, the glyoxysome-localization peptide at the 3' end of the soluble fumarate reductase is partially or completely cleaved and is therefore freely present in the cytoplasm.

[0139] In one embodiment, soluble fumarate reductase activity is generated or increased by expressing or overexpressing a gene encoding a soluble fumarate reductase in a genetically modified succinate producing yeast strain, preferably said gene encoding a soluble fumarate reductase is preferably derived from yeast and Kinetoplastidae (e.g., including but not limited to Saccharomyces cerevisiae, Trypanosoma brucei, Leishmania mexicana and Trypanosoma cruzi).

[0140] In one embodiment, the gene encoding a soluble fumarate reductase comprises a nucleotide sequence encoding an amino acid sequence having any one of SEQ ID NOs: 3 to 5 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having fumarate reductase activity.

[0141] In one embodiment, a gene encoding a soluble fumarate reductase is integrated into the genome of a genetically modified succinic acid producing yeast (e.g., Pichia kudryabzevii), e.g., at the ADH1 locus. The gene encoding a soluble fumarate reductase may be placed under the control of a suitable promoter (e.g., the promoter of the ADH1 gene (as shown in SEQ ID NO:21)) and / or terminator (e.g., the terminator of the ADH1 gene (as shown in SEQ ID NO:22)).

[0142] In a further embodiment, the method further comprises conferring or enhancing succinate transport protein activity in the yeast strain.

[0143] In one embodiment, the succinate transport protein is selected from the group consisting of SpMAE1 protein, AnDCT-02 protein, EcDcuB protein and EcDcuC protein. In one embodiment, the succinate transport protein activity is conferred or enhanced by expressing or overexpressing a gene encoding a succinate transport protein (e.g., SpMAE1 gene) in the genetically modified succinate-producing yeast strain.

[0144] In one embodiment, the SpMAE1 gene comprises a nucleotide sequence encoding an amino acid sequence having a sequence of SEQ ID NO:2 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto, and having succinate transport protein activity, and is optionally integrated (e.g., via homologous recombination) into the genome of a genetically modified succinate-producing yeast strain (e.g., Pichia kudriabzevii), for example, at the MCH4 locus. The SpMAE1 gene may be under the control of a suitable promoter (e.g., the promoter of the TDH3 gene (as shown in SEQ ID NO:19)) and / or terminator (e.g., the terminator of the GAL2 gene (as shown in SEQ ID NO:20)).

[0145] In a further embodiment, the method further comprises conferring or enhancing fumarase activity in the yeast strain.

[0146] In one embodiment, the mitochondrial localization peptide at the 5' end of the fumarase is partially or completely truncated and therefore cannot localize to mitochondria but is free to reside in the cytoplasm.

[0147] In one embodiment, fumarase activity is imparted or enhanced by expressing or overexpressing a gene encoding a fumarase in a genetically modified succinic acid producing yeast strain, such as, but not limited to, Actinobacillus succinogenes, Mannheimia succiniciproducens, Escherichia coli, Pichia kudryabzevi, or Rhizopus oryzae.

[0148] In one embodiment, the fumarase comprises an amino acid sequence of SEQ ID NO: 95, or amino acids having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having fumarase activity.

[0149] In one embodiment, the gene encoding fumarase encodes an amino acid sequence having the amino acid sequence of SEQ ID NO: 95, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having fumarase activity.

[0150] In one embodiment, the gene encoding fumarase comprises a nucleotide sequence encoding an amino acid sequence having the sequence of SEQ ID NO:8 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having fumarase activity.

[0151] Optionally, the gene encoding fumarase is integrated (e.g., via homologous recombination) into the genome of the genetically modified succinic acid-producing yeast (e.g., Pichia kudryabzevii), e.g., at the PDC1 locus. The gene encoding fumarase may be placed under the control of a suitable promoter (e.g., the promoter of the TDH3 gene (shown in SEQ ID NO: 19)) and / or terminator (e.g., the terminator of the GAL2 gene (shown in SEQ ID NO: 20)).

[0152] In a further embodiment, the method further comprises conferring or enhancing pyruvate carboxylase activity in the yeast strain. Preferably, conferring or enhancing pyruvate carboxylase activity is achieved by expressing or overexpressing a gene encoding pyruvate carboxylase in the strain. The pyruvate carboxylase may be derived from a fungus, in particular yeast and filamentous fungi, preferably Saccharomyces cerevisiae, Pichia kudriabzevii, Aspergillus oryzae, Kluyveromyces marxianus, etc. In one embodiment, the gene encoding pyruvate carboxylase may be selected from the group consisting of the PYC gene of Aspergillus oryzae and the PYC1 gene of Pichia kudriabzevii.

[0153] In one embodiment, the pyruvate carboxylase comprises an amino acid sequence encoded by SEQ ID NO: 6 or 7, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having pyruvate carboxylase activity.

[0154] In one embodiment, the gene encoding pyruvate carboxylase comprises a nucleotide sequence encoding an amino acid sequence having the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having pyruvate carboxylase activity.

[0155] Optionally, a gene encoding pyruvate carboxylase is integrated into the genome of a genetically modified succinic acid producing yeast (e.g., Pichia kudriabzevii), for example at the JEN2-1 locus. The gene encoding pyruvate carboxylase may be placed under the control of a suitable promoter (e.g., the promoter of the TDH3 gene (shown in SEQ ID NO: 19)) and / or terminator (e.g., the terminator of the GAL2 gene (shown in SEQ ID NO: 20)).

[0156] According to the method, the gene to be expressed or overexpressed in the strain can be integrated at any suitable position in the genome of the strain, as long as such integration does not adversely affect the growth, proliferation and / or productivity of the strain.For example, the method includes integrating one or more of the above-mentioned genes at any one or more positions in the genome that code for the following proteins: (i) pyruvate decarboxylase (EC 4.1.1.43), (ii) NAD-dependent glycerol 3-phosphate dehydrogenase (EC 1.1.1.8), (iii) orotidine 5'-phosphate decarboxylase (EC 4.1.1.23), (iv) monocarboxylate permease, (v) dicarboxylate transport protein, (vi) alcohol dehydrogenase 1 (EC 1.1.1.1), and (vii) bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase (EC 4.1.3.17 or 4.1.1.112).

[0157] In a further embodiment, the method further comprises attenuating or inactivating in the strain at least one of: (i) pyruvate decarboxylase (EC 4.1.1.43); (ii) NAD-dependent glycerol 3-phosphate dehydrogenase (EC 1.1.1.8); (iii) orotidine 5'-phosphate decarboxylase (EC 4.1.1.23); (iv) monocarboxylate permease; (v) dicarboxylate transport protein; (vi) alcohol dehydrogenase 1 (EC 1.1.1.1); and (vii) the bifunctional enzyme oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase (EC 4.1.3.17 or 4.1.1.112).

[0158] In a further embodiment, the method further comprises reducing or inactivating pyruvate decarboxylase activity in the yeast strain.

[0159] As used herein, reducing or inactivating the activity of a protein such as an enzyme means that the activity of the protein is reduced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or more, or even undetectable.There are various means in the art for reducing and inactivating, including, for example, inhibiting gene expression, such as knockdown (e.g., using small interfering RNA), using weak promoters (if the gene is a polypeptide-encoding gene), gene knockout and deletion of partial or complete sequences of genes or polypeptides, mutating specific loci, such as coding sequences or active domains in genes or polypeptides to reduce gene expression or regulate activity or express the activity of products, and using antagonists or inhibitors (e.g., including but not limited to antibodies, interfering RNA, etc.).

[0160] As used herein, weakening or inactivating a gene means that the expression level (when used as a protein-coding gene) or regulatory performance (when used as a regulatory element) of the gene is reduced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or more, or even undetectable. There are various means in the art for weakening or inactivating a gene, such as inhibition of gene expression, such as knockdown (e.g., using small interfering RNA), use of weak promoters (when the gene is a polypeptide-coding gene), gene knockout and deletion of partial or all gene sequences, mutation of specific loci, such as coding sequences in the gene, to reduce gene expression or regulate activity or express the activity of the product, etc.

[0161] In one embodiment, reducing or inactivating pyruvate decarboxylase activity comprises attenuating or inactivating a gene encoding pyruvate decarboxylase.

[0162] In one embodiment, attenuating or inactivating the gene encoding pyruvate decarboxylase comprises knocking out the gene encoding pyruvate decarboxylase (e.g., an amino acid sequence of SEQ ID NO: 10, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having pyruvate decarboxylase activity).

[0163] In a further embodiment, the method further comprises reducing or inactivating NAD-dependent glycerol 3-phosphate dehydrogenase activity in the yeast strain.

[0164] In one embodiment, reducing or inactivating the NAD-dependent glycerol 3-phosphate dehydrogenase activity comprises weakening or inactivating a gene encoding an NAD-dependent glycerol 3-phosphate dehydrogenase. In one embodiment, weakening or inactivating a gene encoding an NAD-dependent glycerol 3-phosphate dehydrogenase comprises knocking out a gene encoding an NAD-dependent glycerol 3-phosphate dehydrogenase (e.g., an amino acid sequence of SEQ ID NO: 11, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having NAD-dependent glycerol 3-phosphate dehydrogenase activity).

[0165] In a further embodiment, the method further comprises reducing or inactivating the activity of orotidine 5'-phosphate decarboxylase and / or alcohol dehydrogenase 1 and / or monocarboxylate permease and / or dicarboxylate transport protein and / or the bifunctional enzyme oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase in the yeast strain.

[0166] In one embodiment, the method includes attenuating or inactivating one or more of a gene encoding orotidine 5'-phosphate decarboxylase, a gene encoding a dicarboxylate transport protein (e.g., a JEN2 gene, e.g., a JEN2-1 gene, a JEN2-2 gene), a gene encoding alcohol dehydrogenase 1, a gene encoding a monocarboxylate permease, and a gene encoding the bifunctional enzyme oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase in a yeast strain.

[0167] In one embodiment, a gene encoding a bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase (e.g., encoding an amino acid sequence of SEQ ID NO: 9, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having the bifunctional enzyme activity of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase) is knocked out, e.g., by homologous recombination.

[0168] In one embodiment, the gene encoding orotidine 5'-phosphate decarboxylase (encoding an amino acid sequence of SEQ ID NO: 13, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having orotidine 5'-phosphate decarboxylase activity) is knocked out, for example by homologous recombination.

[0169] In one embodiment, the JEN2-1 gene encoding a dicarboxylate transport protein (e.g., encoding an amino acid sequence of SEQ ID NO: 14, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having dicarboxylate transport protein activity) is knocked out, e.g., by homologous recombination.

[0170] In one embodiment, the JEN2-2 gene, which encodes a dicarboxylate transport protein (e.g., an amino acid sequence of SEQ ID NO: 15, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having dicarboxylate transport protein activity), is knocked out, e.g., by homologous recombination.

[0171] In one embodiment, the gene encoding alcohol dehydrogenase 1 (encoding an amino acid sequence of SEQ ID NO: 12, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having alcohol dehydrogenase 1 activity) is knocked out, for example by homologous recombination.

[0172] In one embodiment, a gene encoding a monocarboxylate permease (e.g., encoding an amino acid sequence of SEQ ID NO: 16, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having monocarboxylate permease activity) is knocked out, e.g., by homologous recombination.

[0173] In one embodiment, the present invention provides a method for producing a genetically modified succinic acid producing yeast strain (e.g., Pichia kudryabzevi, e.g., CY902), comprising overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase in the genetically modified succinic acid producing yeast strain, and optionally knocking out an endogenous gene encoding orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding the bifunctional enzymes oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase.

[0174] In one embodiment, the present invention provides a method for producing a genetically modified succinic acid producing yeast strain (e.g., Pichia kudryabzevi, e.g., CY902), comprising overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase and a gene encoding a soluble fumarate reductase in the genetically modified succinic acid producing yeast strain, and optionally knocking out an endogenous gene encoding orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding alcohol dehydrogenase 1 and / or an endogenous gene encoding the bifunctional enzymes oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase.

[0175] In one embodiment, the present invention provides a method for producing a genetically modified succinic acid producing yeast strain (e.g., Pichia kudryabzevi, e.g., CY902), comprising overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase and a gene encoding a succinate transport protein, e.g., SpMAE1 gene, in the genetically modified succinic acid producing yeast strain, and optionally knocking out an endogenous gene encoding orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding a monocarboxylate permease and / or an endogenous gene encoding a bifunctional enzyme, oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase, in the genetically modified succinic acid producing yeast strain.

[0176] In one embodiment, the present invention provides a method for producing a genetically modified succinic acid producing yeast strain (e.g., Pichia kudryabzevi, e.g., CY902), comprising overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase and a gene encoding a fumarase in the genetically modified succinic acid producing yeast strain, and optionally knocking out an endogenous gene encoding orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding pyruvate decarboxylase and / or an endogenous gene encoding the bifunctional enzymes oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase.

[0177] In one embodiment, the present invention provides a method for producing a genetically modified succinic acid producing yeast strain (e.g., Pichia kudryabzevi, e.g., CY902), comprising overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase and a gene encoding pyruvate carboxylase in the genetically modified succinic acid producing yeast strain, and optionally knocking out an endogenous gene encoding orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding a dicarboxylate transport protein, e.g., the JEN2-1 or JEN2-2 gene and / or an endogenous gene encoding the bifunctional enzyme oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase.

[0178] In one embodiment, the present invention provides a method for producing a genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevi, e.g., CY902), comprising overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase and a gene encoding a pyruvate carboxylase in the genetically modified succinic acid producing yeast strain, knocking out an endogenous gene encoding a pyruvate decarboxylase and an endogenous gene encoding an NAD-dependent glycerol 3-phosphate dehydrogenase, and optionally knocking out an endogenous gene encoding an orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding a dicarboxylate transport protein (e.g., a JEN2 gene, e.g., a JEN2-1 gene, a JEN2-2 gene) and / or an endogenous gene encoding a bifunctional enzyme, oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase.

[0179] In one embodiment, the present invention provides a method for producing a genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevii, e.g., CY902), comprising overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase, a gene encoding a pyruvate carboxylase, a gene encoding a soluble fumarate reductase, and a gene encoding a succinate transport protein, e.g., SpMAE1 gene, and knocking out an endogenous gene encoding pyruvate decarboxylase and an endogenous gene encoding an NAD-dependent glycerol 3-phosphate dehydrogenase in the genetically modified succinic acid producing yeast strain. and optionally knocking out an endogenous gene encoding orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding a dicarboxylate transport protein (e.g., a JEN2 gene, e.g., a JEN2-1 gene, a JEN2-2 gene) and / or an endogenous gene encoding a bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase and / or an endogenous gene encoding alcohol dehydrogenase 1 and / or an endogenous gene encoding a monocarboxylate permease. Preferably, the MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or the gene encoding pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof, the gene encoding soluble fumarate reductase comprises the sequence of any one of SEQ ID NOs: 3 to 5 or a degenerate sequence thereof, the gene encoding fumarase comprises the sequence of SEQ ID NO: 8 or a degenerate sequence thereof, or the gene encoding succinate transport protein comprises the sequence of SEQ ID NO: 2 or a degenerate sequence thereof.

[0180] In one embodiment, the present invention provides a method for producing a genetically modified succinic acid producing yeast strain (e.g., Pichia kudriabzevii, e.g., CY902), comprising overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase, a gene encoding a pyruvate carboxylase, a gene encoding a soluble fumarate reductase, a gene encoding a fumarase, and a gene encoding a succinate transport protein, e.g., SpMAE1 gene, in the genetically modified succinic acid producing yeast strain, and overexpressing an endogenous gene encoding pyruvate decarboxylase and an endogenous gene encoding an NAD-dependent glycerol 3-phosphate dehydrogenase. and optionally knocking out an endogenous gene encoding an orotidine 5'-phosphate decarboxylase and / or an endogenous gene encoding a dicarboxylate transport protein (e.g., a JEN2 gene, e.g., a JEN2-1 gene, a JEN2-2 gene) and / or an endogenous gene encoding a bifunctional enzyme, oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase and / or an endogenous gene encoding alcohol dehydrogenase 1 and / or an endogenous gene encoding a monocarboxylate permease. Preferably, the MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, the gene encoding pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof, the gene encoding soluble fumarate reductase comprises the sequence of any one of SEQ ID NOs: 3 to 5 or a degenerate sequence thereof, the gene encoding fumarase comprises the sequence of SEQ ID NO: 8 or a degenerate sequence thereof, or the gene encoding succinate transport protein comprises the sequence of SEQ ID NO: 2 or a degenerate sequence thereof.

[0181] In one embodiment, the present invention provides a method for producing a genetically modified Pichia kudriabzevi, such as strain CY902, comprising overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase, and optionally knocking out the endogenous URA3 gene and / or the endogenous Pk2365 gene. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof.

[0182] In one embodiment, the present invention provides a method for producing a genetically modified Pichia kudriabzevi, such as strain CY902, comprising overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase and a gene encoding a soluble fumarate reductase, and optionally knocking out an endogenous URA3 gene and / or an endogenous ADH1 gene and / or an endogenous Pk2365 gene. Preferably, the MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or the gene encoding a soluble fumarate reductase comprises the sequence of any one of SEQ ID NOs: 3-5 or a degenerate sequence thereof.

[0183] In one embodiment, the present invention provides a method for producing a genetically modified Pichia kudriabzevi, such as the CY902 strain, comprising overexpressing the MDH gene encoding an NADPH-dependent malate dehydrogenase and a gene encoding a succinate transport protein, such as the SpMAE1 gene, and optionally knocking out the endogenous URA3 gene and / or the endogenous MCH4 gene and / or the endogenous Pk2365 gene. Preferably, the MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate thereof, or the gene encoding a succinate transport protein comprises the sequence of SEQ ID NO: 2 or a degenerate thereof.

[0184] In one embodiment, the present invention provides a method for producing a genetically modified Pichia kudriabzevi, such as strain CY902, comprising overexpressing the MDH gene encoding NADPH-dependent malate dehydrogenase and the gene encoding fumarase, and optionally knocking out the endogenous URA3 gene and / or the endogenous PDC1 gene and / or the endogenous Pk2365 gene. Preferably, the MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate thereof, or the gene encoding fumarase comprises the sequence of SEQ ID NO: 8 or a degenerate thereof.

[0185] In one embodiment, the present invention provides a method for producing a genetically modified Pichia kudriabzevi, such as strain CY902, comprising overexpressing the MDH gene encoding NADPH-dependent malate dehydrogenase and the gene encoding pyruvate carboxylase, and optionally knocking out the endogenous URA3 gene and / or the endogenous JEN2-1 or JEN2-2 gene and / or the endogenous Pk2365 gene. Preferably, said MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate thereof, or said gene encoding pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate thereof.

[0186] In one embodiment, the present invention provides a method for producing a genetically modified Pichia kudriabzevi, such as the CY902 strain, comprising overexpressing the MDH gene encoding NADPH-dependent malate dehydrogenase and the gene encoding pyruvate carboxylase, knocking out the endogenous PDC1 gene and the endogenous GPD1 gene, and optionally knocking out the endogenous URA3 gene and / or the endogenous JEN2 gene, such as the JEN2-1 gene, the JEN2-2 gene, and / or the endogenous Pk2365 gene. Preferably, the MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or the gene encoding pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof.

[0187] In one embodiment, the present invention provides a method for producing a genetically modified Pichia kudriabzevi, for example the CY902 strain, comprising overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase, a gene encoding a pyruvate carboxylase, a gene encoding a soluble fumarate reductase and a gene encoding a succinate transport protein, for example the SpMAE1 gene, knocking out an endogenous PDC1 gene and an endogenous GPD1 gene, and optionally knocking out an endogenous URA3 gene and / or an endogenous JEN2 gene, for example the JEN2-1 gene, the JEN2-2 gene, and / or the endogenous Pk2365 gene and / or the endogenous ADH1 gene and / or the endogenous MCH4 gene. Preferably, the MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or the gene encoding pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof, the gene encoding soluble fumarate reductase comprises the sequence of any one of SEQ ID NOs: 3 to 5 or a degenerate sequence thereof, or the gene encoding succinate transport protein comprises the sequence of SEQ ID NO: 2 or a degenerate sequence thereof.

[0188] In one embodiment, the present invention provides a method for producing a genetically modified Pichia kudriabzevi, such as the CY902 strain, comprising overexpressing an MDH gene encoding an NADPH-dependent malate dehydrogenase, a gene encoding a pyruvate carboxylase, a gene encoding a soluble fumarate reductase, a gene encoding a fumarase and a gene encoding a succinate transport protein, such as the SpMAE1 gene, knocking out an endogenous PDC1 gene and an endogenous GPD1 gene, and optionally knocking out an endogenous URA3 gene and / or an endogenous JEN2 gene, such as the JEN2-1 gene, JEN2-2 gene and / or an endogenous Pk2365 gene and / or an endogenous ADH1 gene and / or an endogenous MCH4 gene. Preferably, the MDH gene comprises the sequence of SEQ ID NO: 1 or a degenerate sequence thereof, or the gene encoding pyruvate carboxylase comprises the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof, the gene encoding soluble fumarate reductase comprises the sequence of any one of SEQ ID NOs: 3 to 5 or a degenerate sequence thereof, or the gene encoding fumarase comprises the sequence of SEQ ID NO: 8 or a degenerate sequence thereof, or the gene encoding succinate transport protein comprises the sequence of SEQ ID NO: 2 or a degenerate sequence thereof.

[0189] In one embodiment, the succinic acid producing yeast strain to be genetically modified includes, but is not limited to, Candida, Pichia, Rhodotorula, Saccharomyces, Yarrowia, Zygosaccharomyces, and Torulopsis. In one embodiment, the succinic acid producing yeast strain used to perform genetic modification is selected from the group consisting of Pichia species, Saccharomyces species, or Yarrowia species. In a preferred embodiment, the succinic acid producing yeast strain used to perform genetic modification is Pichia kudriabzevi, Saccharomyces cerevisiae, or Yarrowia lipolytica, such as Pichia kudriabzevi, which is deposited at the China General Microorganism Center (CGMCC) under the deposit number CGMCC No. 20885.

[0190] In one aspect, the present invention provides a method for producing succinic acid, comprising culturing a genetically modified succinic acid-producing yeast strain according to the present invention or a genetically modified succinic acid-producing yeast strain prepared by a method for constructing a genetically modified succinic acid-producing yeast strain according to the present invention under conditions suitable for the fermentative production of succinic acid, and optionally isolating and purifying the produced succinic acid.

[0191] The conditions for the fermentative production of succinic acid under which the succinic acid producing yeast strain is cultured by fermentation are known in the art, including but not limited to pH, temperature, culture medium components, fermentation time, etc.

[0192] The culture medium for the fermentative production of succinic acid by succinic acid-producing yeast strains includes a mineral salts culture medium (approximately 5-12% w / v glucose, optionally 30 g / L CaCO 3 These include, but are not limited to, those containing

[0193] The temperature for fermentation production of succinic acid by a succinic acid-producing yeast strain is known to be, for example, about 25 to 37° C., for example, about 25° C., about 26° C., about 27° C., about 28° C., about 29° C., about 30° C., about 31° C., about 32° C., about 33° C., about 34° C., about 35° C., about 36° C., or about 37° C. In one embodiment, the succinic acid-producing yeast strain of the present invention is fermented at 30° C. to produce succinic acid.

[0194] The succinic acid producing yeast strain of the present invention can be grown at any suitable pH known in the art, for example, less than about 7.0, less than about 6.5, less than about 6.0, less than about 5.5, less than about 5.0, less than about 4.5, less than about 4.0, less than about 3.5, less than about 3.0, less than about 2.5, less than about 2.0, less than about 1.5, less than about 1.0 (e.g., about 1.0 to 7.0, 1.0 to 6.0, 1.0 to 5.5, 1.0 to 5.0, 1.0 to 4.5, 1.0 to 4.0, 1.0 to 3.5, The yeast strain may be fermented at a pH value of 1.0-3.0, 2.0-7.0, 2.0-6.0, 2.0-5.5, 2.0-5.0, 2.0-4.5, 2.0-4.0, 2.0-3.5, 2.0-3.0, 3.0-7.0, 3.0-6.0, 3.0-5.5, 3.0-5.0, 3.0-4.5, 3.0-4.0, 3.0-3.5, 4.0-7.0, 4.0-6.0, 4.0-5.5, 4.0-5.0, 4.0-4.5). In one embodiment, the succinic acid producing yeast strain of the present invention is fermented at a pH of less than about 3.0 to produce succinic acid.

[0195] To produce succinic acid, the succinic acid producing yeast strain of the present invention may be fermented for a suitable time, for example, about 12 to 96 hours, for example, about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, about 72 hours, or about 96 hours. In one embodiment, to produce succinic acid, the succinic acid producing yeast strain of the present invention may be fermented for about 24 to 72 hours, for example, about 30 hours.

[0196] The succinic acid producing yeast strain of the present invention may be fermented under shaking conditions (eg, about 100-300 rpm, such as about 150, about 200, or about 250 rpm) to produce succinic acid.

[0197] The content of succinic acid in the fermentation broth can be determined by any method known in the art, such as high performance liquid chromatography (HPLC).

[0198] In one embodiment, the present invention provides a method for producing succinic acid, comprising culturing a genetically modified succinic acid producing yeast strain in a mineral salts culture medium (e.g., about 5% w / v glucose and about 30 g / L CaCO 3or containing about 12% w / v glucose), at an acidic pH (less than about 7.0, less than about 6.5, less than about 6.0, less than about 5.5, less than about 5.0, less than about 4.5, less than about 4.0, less than about 3.5, less than about 3.0, less than about 2.5, less than about 2.0, less than about 1.5, less than about 1.0, e.g., about 1.0-7.0, 1.0-6.0, 1.0-5.5, 1.0-5.0, 1.0-4.5, 1.0-4.0, 1.0-3.5, 1.0-3.0, 2.0-7.0, 2.0-3.5, 2.0-4.5, 2.0-5.5, 2.0-6.0, 2.0-7.0, 2.0-8.0, 2.0-8.0, 2.0-9.0, 2.0-10.0, 2.0-11.0, 2.0-12.0, 2.0-13.0, 2.0-14.0, 2.0-15.0, 2.0-16.0, 2.0-17.0, 2.0-18.0, 2.0-19 ... and optionally isolating and purifying the produced succinic acid.

[0199] In one embodiment, the addition of a neutralizing agent is not required in the method of producing succinic acid of the present invention.

[0200] In one aspect, the present invention relates to the production of succinic acid, particularly at an acidic pH (less than about 7.0, less than about 6.5, less than about 6.0, less than about 5.5, less than about 5.0, less than about 4.5, less than about 4.0, less than about 3.5, less than about 3.0, less than about 2.5, less than about 2.0, less than about 1.5, less than about 1.0, e.g., about 1.0-7.0, 1.0-6.0, 1.0-5.5, 1.0-5.0, 1.0-4.5, 1.0-4.0, 1.0-3.5, 1.0-3.0, 2.0-7.0, 2.0-6.0, 2.0-5.5, 2.0-5.0, 2.0-4.5, 2.0-4. The present invention provides use of the genetically modified succinic acid-producing yeast strain of the present invention or a genetically modified succinic acid-producing yeast strain prepared by the method of constructing the genetically modified succinic acid-producing yeast strain of the present invention in the production of succinic acid under conditions of (a) 0.0, 2.0-3.5, 2.0-3.0, 3.0-7.0, 3.0-6.0, 3.0-5.5, 3.0-5.0, 3.0-4.5, 3.0-4.0, 3.0-3.5, 4.0-7.0, 4.0-6.0, 4.0-5.5, 4.0-5.0, 4.0-4.5) and / or without the addition of a neutralizing agent.

[0201] As used herein, "optional" or "optionally" refers to the occurrence or non-occurrence of a subsequently described event or circumstance, and such a description includes the occurrence and non-occurrence of the event or circumstance described therein. For example, an optionally included step refers to the presence or absence of that step.

[0202] As used herein, the term "about" refers to a range of numbers that includes the specified value that can be reasonably considered similar to the specified value by one of ordinary skill in the art. In some embodiments, the term "about" refers to a range within the standard error using measurements normally accepted in the art. In some embodiments, the term "about" refers to + / - 10% of the specified value.

[0203] Ranges disclosed herein should also be considered to specifically disclose all possible subranges and various values ​​within such ranges. For example, description of a range from 1 to 6 should be considered to explicitly disclose subranges such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, and 3 to 6, as well as single numbers within this range, such as 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0204] The present invention will be further described by the following non-limiting examples. It is well known to those skilled in the art that the present invention can be modified in various ways without departing from the spirit of the present application, and such modifications are also included in the scope of the present invention.

[0205] Unless otherwise stated, the following experimental methods are conventional methods and the experimental materials used are readily available from commercial companies.

[0206] Example 1: Overexpression of the SbMDH gene in Pichia kudriabzevii CY902ΔURA3 strain The ΔURA3 mutant was obtained by knocking out the gene URA3 encoding orotidine 5'-phosphate decarboxylase (at locus PK2075 of CY902) by homologous recombination (Xi, Y.; Zhan, T.; Xu, H.; Chen, J.; Bi, C.; Fan, F.; Zhang, X., Characterization of JEN family carboxylate transporters from the acid-tolerant yeast Pichia kudriavzevii and their applications in succinate production. Microb Biotechnol 2021.0(0),1-18.doi:10.1111 / 1751-7915.13781). Subsequently, a suitable CRISPR / Cas9 plasmid pWSPK-Cas9 (GenBank search number: MW296878.1) for this strain was constructed. This plasmid contains the URA3 screening marker, which allowed to obtain positive transformants by auxotrophic screening.

[0207] Using CY902ΔURA3 as the starting strain, the malate dehydrogenase SbMDH (Uniprot database search number: P17606) (SEQ ID NO: 1) derived from Sorghum bicolor was overexpressed at the locus Pk2365 of the CY902 genome, and the promoter and terminator used were the promoter (SEQ ID NO: 17) of the gene FBA1 encoding fructose 1,6-bisphosphate aldolase of CY902 itself and the terminator (SEQ ID NO: 18) of the inositol-3-phosphate synthase gene INO1 of CY902 itself, respectively. The SbMDH gene was synthesized by Nanjing GenScript Biotech Co.,Ltd and optimized according to the codon selection of CY902. The specific construction method was as follows.

[0208] 1. Construction of donor DNA fragment for homologous recombination Using CY902 genomic DNA as a template, the upstream homology arm fragment 1 (fragment 1) of the Pk2365 gene of CY902 itself was amplified with primers 1_UP_2365_F and 1_UP_2365_R1 (see Table 1). The amplification system and procedure were based on the product specifications of TAKARA PrimeSTAR® HS DNA polymerase. The FBA1 promoter sequence of CY902 itself (fragment 2) was amplified with primer 2_P FBA1 _F and 2_P FBA1 The SbMDH coding sequence of Sorghum bicolor (fragment 3) was amplified with primers 3_SbMDH_F and 3_SbMDH_R (see Table 1) using a plasmid containing the SbMDH synthetic sequence as a template. The INO1 gene terminator sequence of CY902 itself (fragment 4) was amplified with primers 4_T and 4_T using CY902 genomic DNA as a template. INO1 _F and 4_T INO1 _R (see Table 1). Downstream homologous arm fragment 1 (fragment 5) of the Pk2365 gene of CY902 itself was amplified with primers 5_DW_2365_F1 and 5_DW_2365_R (see Table 1). Upstream homologous arm fragment 2 (fragment 6) of the Pk2365 gene of CY902 itself was amplified with primers 1_UP_2365_F and 1_UP_2365_R2 (see Table 1) using CY902 genomic DNA as a template. Downstream homologous arm fragment 2 (fragment 7) of the Pk2365 gene of CY902 itself was amplified with primers 5_DW_2365_F2 and 5_DW_2365_R (see Table 1).

[0209] 2. Construction of plasmids for editing the Pk2365 locus Using the pWSPK-Cas9 plasmid (GenBank search number: MW296878.1) as a template, a 9052 bp plasmid backbone (abbreviated as pWSPK_backbone, SEQ ID NO: 23) without sgRNA sequence was amplified with primers pWSPK-F and pWSPK-R (see Table 1). The 5'-terminal sequence of the sgRNA (GenBank search number: MW296878.1) (abbreviated as 2365_sgRNA_1) was amplified with primers sgRNA-1F and 2365_sgRNA-1R (see Table 1), and the 3'-end of the fragment contained a 20 nt protospacer specific for the Pk2365 gene. Using the pWSPK-Cas9 plasmid as a template, a 500 bp 3' sequence of the sgRNA (abbreviated as sgRNA_2, SEQ ID NO: 97) was amplified with primers sgRNA-2F and sgRNA-2R (see Table 1). The above plasmid backbone pWSPK_backbone and sgRNA fragments 2365_sgRNA_1 and sgRNA_2 were ligated using a seamless cloning kit (Beyotime Biotechnology Co., Ltd., Shanghai, Product No.: D7010S). The seamless cloning ligation product was transferred into Trans1-T1 competent cells (TransGen Biotech Co., Ltd., Beijing, Product No.: CD501-02), and the resulting positive plasmid was named pWSPK_2365.

[0210] 3. Construction of a strain overexpressing the SbMDH gene The pWSPK_2365 plasmid and fragments 6 and 7 were transferred into the CY902ΔURA3 strain by yeast electrotransformation (doi:10.1111 / 1751-7915.13781), and a positive transformant was screened and obtained, and named SA101-1 strain (genotype: CY902ΔURA3, ΔPk2365). The pWSPK_2365 plasmid and fragments 1-5 were transferred into the CY902ΔURA3 strain by yeast electrotransformation, and a positive transformant was screened and obtained, and named SA101-2 strain (genotype: CY902ΔURA3, Pk2365::P PkFBA1 -ORF SbMDH -T PkINO1 ) and named it.

[0211] [Table 1]

[0212] Example 2: Overexpression of EcSthA and AoMDH genes in Pichia kudriabzevii CY902ΔURA3 Using CY902ΔURA3 as the starting strain, the E. coli derived soluble pyridine nucleotide transhydrogenase EcSthA (EC1.6.1.1) (SEQ ID NO: 98) was overexpressed at locus Pk2365 of the CY902 genome, and the promoter and terminator used were CY902's own FBA1 promoter (SEQ ID NO: 17) and INO1 terminator (SEQ ID NO: 18), respectively. Aspergillus oryzae derived malate dehydrogenase AoMDH (EC1.1.1.37, Uniprot database search number: I8U0T6) (SEQ ID NO: 99) was overexpressed in the locus of succinic semialdehyde dehydrogenase (EC1.2.1.16) gene PkUGA2, and the promoter and terminator used were the promoter of CY902's own enolase gene ENO1 (SEQ ID NO: 100) and the terminator of the gene SED1 encoding a GPI cell wall glycoprotein (SEQ ID NO: 101), respectively. The EcSthA and AoMDH genes were synthesized by Nanjing GenScript Biotech Co.,Ltd and optimized by the codon selection of CY902. The specific construction method was as follows.

[0213] 1. Construction of donor DNA fragment for homologous recombination Using a plasmid containing the EcSthA synthetic sequence as a template, the sequence encoding EcSthA, a soluble pyridine nucleotide transhydrogenase of E. coli (fragment 8), was amplified with primers 3_EcSthA_F and 3_EcSthA_R (see Table 2). Using CY902 genomic DNA as a template, the upstream homology arm fragment 1 of the PkUGA2 gene of CY902 itself (fragment 9) was amplified with primers 1_UP_UGA2_F and 1_UP_UGA2_R1 (see Table 2). The ENO1 promoter sequence of CY902 itself (fragment 10) was amplified with primers 2_P ENO1 _F and 2_P ENO1 The Aspergillus oryzae AoMDH coding sequence (fragment 11) was amplified with primers 3_AoMDH_F and 3_AoMDH_R (see Table 2) using a plasmid containing the AoMDH synthetic sequence as a template. The SED1 gene terminator sequence of CY902 itself (fragment 12) was amplified with primers 4_T and 4_T using CY902 genomic DNA as a template. SED1 _F and 4_T SED1 _R (see Table 1). Downstream homology arm fragment 1 (fragment 13) of the PkUGA2 gene of CY902 itself was amplified with primers 5_DW_UGA2_F1 and 5_DW_UGA2_R (see Table 2). Upstream homology arm fragment 2 (fragment 14) of the PkUGA2 gene of CY902 itself was amplified with primers 1_UP_UGA2_F and 1_UP_UGA2_R2 (see Table 2) using CY902 genomic DNA as a template. Downstream homology arm fragment 2 (fragment 15) of the PkUGA2 gene of CY902 itself was amplified with primers 5_DW_UGA2_F2 and 5_DW_UGA2_R (see Table 2).

[0214] 2. Construction of plasmids for editing the PkUGA2 locus Using the pWSPK-Cas9 plasmid as a template, the 5'-end sequence of sgRNA (abbreviated as UGA2_sgRNA_1) was amplified with primers sgRNA-1F and UGA2_sgRNA-1R (see Table 2), and the 3'-end of the fragment contained a 20-nt protospacer specific for the PkUGA2 gene. The pWSPK_backbone, sgRNA_2 and UGA2_sgRNA_1 were ligated using a seamless cloning kit, finally obtaining a positive cloning plasmid named pWSPK_UGA2.

[0215] 3. Construction of strains overexpressing EcSthA and AoMDH genes The pWSPK_2365 plasmid and fragments 1, 2, 8, 4 and 5 were transferred into the CY902ΔURA3 strain by yeast electrotransformation, and positive transformants were screened to obtain SA101-3 strain (genotype: CY902ΔURA3, Pk2365::P PkFBA1 -ORF EcSthA -T PkINO1 The pWSPK_UGA2 plasmid and fragments 14 and 15 were transferred to SA101-2 and SA101-3 strains by yeast electrotransformation, and positive transformants were screened and named SA102-1 strain (genotype: SA101-2, ΔUGA2) and SA102-2 strain (SA101-3, ΔUGA2), respectively. The pWSPK_UGA2 plasmid and fragments 9 to 13 were transferred to SA101-3 strain by yeast electrotransformation, and positive transformants were screened and named SA102-3 strain (genotype: SA101-3, PkUGA2::P PkENO1 -ORF AoMDH -T PkSED1 ) and named it.

[0216] [Table 2]

[0217] Example 3: Evaluation of succinic acid production ability of SA101 and SA102 series strains 1. Fermentation using neutralizing agents 30 mL of yeast mineral salts culture medium (5% w / v glucose, 30 g / L CaCO 3 ) was inoculated with the strains of the SA101 and SA102 series and fermented in a shaking flask at 30°C and 250 rpm for 24 hours. The succinic acid titer was measured by HPLC and is shown in Table 3 below.

[0218] [Table 3]

[0219] 2. Fermentation without neutralizing agents 30 mL of yeast mineral salts culture medium (5% w / v glucose, 0 g / L CaCO 3 ) was inoculated with the strains of the SA101 and SA102 series, and fermented with shaking flasks at 30°C and 250 rpm for 24 hours. The succinic acid titer was then measured by HPLC and is shown in Table 4 below.

[0220] [Table 4]

[0221] Example 4: Overexpression of FRD gene in SA101-2 strain Using SA101-2 as the starting strain, three sources of fumarate reductase were overexpressed at the locus of ADH1 gene, including (I) FRD of Saccharomyces cerevisiae (ScFRD, Uniprot database search number: P32614) (SEQ ID NO: 3), (II) FRD of Leishmania mexicana (LmFRD, SEQ ID NO: 4), and (III) FRD of Trypanosoma brucei (TbFRD, SEQ ID NO: 5). The promoter and terminator for overexpressing FRD were the promoter (SEQ ID NO: 21) and terminator (SEQ ID NO: 22) of alcohol dehydrogenase 1 ADH1 of CY902 itself, respectively. The above three FRD gene sequences were synthesized by Nanjing GenScript Biotech Co.,Ltd and optimized according to the codon selection of CY902. The specific construction method was as follows:

[0222] 1. Construction of donor DNA fragment for homologous recombination Using CY902 genomic DNA as a template, the ADH1 gene promoter sequence of CY902 itself (upstream homology arm, fragment 16) was amplified using primer 1_P ADH1 _F and 1_P ADH1_R (see Table 5). Using a plasmid containing the ScFRD synthetic sequence as a template, the ScFRD coding sequence of Saccharomyces cerevisiae (fragment 17-1) was amplified with primers 2_ScFRD_F and 2_ScFRD_R (see Table 5). Using a plasmid containing the LmFRD synthetic sequence as a template, the LmFRD coding sequence of Leishmania mexicana with the 3'-terminal glyoxysome localization peptide truncated (fragment 17-2) was amplified with primers 2_LmFRD_F and 2_LmFRD_R (see Table 5). Using a plasmid containing the TbFRD synthetic sequence as a template, the TbFRD coding sequence of Trypanosoma brucei with the 3'-terminal glyoxysome localization peptide truncated (fragment 17-3) was amplified with primers 2_TbFRD_F and 2_TbFRD_R (see Table 5). Using CY902 genomic DNA as a template, the ADH1 gene terminator sequence of CY902 itself (downstream homology arm 1, fragment 18) was amplified by primer 3_T ADH1 _F1 and 3_T ADH1 _R (see Table 5). The CY902 genomic DNA was used as a template, and the ADH1 gene terminator sequence of CY902 itself (downstream homology arm 2, fragment 19) was amplified with primer 3_T ADH1 _F2 and 3_T ADH1 _R (see Table 5).

[0223] 2. Construction of Plasmids for Editing the ADH1 Locus Using the pWSPK-Cas9 plasmid as a template, the 5'-end sequence of sgRNA (abbreviated as ADH1_sgRNA_1) was amplified with primers sgRNA-1F and ADH1_sgRNA-1R (see Table 5), and the 3'-end of this fragment contained a 20-nt protospacer specific for the Pichia kudriabzevi ADH1 (PkADH1) gene. The pWSPK_backbone, sgRNA_2 and ADH1_sgRNA_1 were ligated using a seamless cloning kit to finally obtain a positive cloning plasmid named pWSPK_ADH1.

[0224] 3. Construction of strains overexpressing FRD genes The pWSPK_ADH1 plasmid and fragments 16 and 19 were transferred into SA101-2 strain according to the yeast electrotransformation method, and a positive cloning transformant was screened and obtained, and named SA103-1 strain (genotype: SA101-2, ΔADH1). The pWSPK_ADH1 plasmid and fragments 16, 17 and 18 were transferred into SA101-2 strain according to the yeast electrotransformation method, respectively, and a positive cloning transformant was screened and obtained, and named SA103-2 strain (genotype: SA101-2, ADH1::ORF ScFRD ), SA103-3 strain (genotype: SA101-2, ADH1::ORF LmFRD ), SA103-4 strain (genotype: SA101-2, ADH1::ORF TbFRD ) and named it.

[0225] [Table 5]

[0226] Example 5: Knockout of PDC1 and GPD1 genes in the SA101-2 strain 1. Construction of DNA fragments to knock out the PDC1 and GPD1 genes Using CY902 genomic DNA as a template, the upstream and downstream homology arm fragments of the PDC1 gene (abbreviated as PDC1_1 and PDC1_2) were amplified with primers PDC1_1F and PDC1_1R, PDC1_2F and PDC1_2R (see Table 6). The upstream and downstream homology arm fragments of the GPD1 gene (abbreviated as GPD1_1 and GPD1_2) were amplified with primers GPD1_1F and GPD1_1R, GPD1_2F and GPD1_2R (see Table 6).

[0227] 2. Construction of CRISPR / Cas9 plasmids for editing the PDC1 and GPD1 genes The 5'-end sequence of the sgRNA (abbreviated as PDC1_sgRNA_1, SEQ ID NO: 96) was amplified with primers sgRNA-1F and PDC1_sgRNA-1R (see Table 6), and the 3'-end of this fragment contained a 20-nt protospacer specific to the PDC1 gene. The plasmid backbone pWSPK_backbone and the sgRNA fragments PDC1_sgRNA_1 and sgRNA_2 were ligated using a seamless cloning kit. The seamless cloning ligation product was transferred into Trans1-T1 competent cells, and the resulting positive plasmid was named pWSPK_PDC1. The 5'-end sequence of the sgRNA (abbreviated as GPD1_sgRNA_1) was amplified with primers sgRNA-1F and GPD1_sgRNA-1R (see Table 6), and the 3'-end of this fragment contained a 20-nt protospacer specific to the GPD1 gene. The pWSPK_backbone, sgRNA_2 and GPD1_sgRNA_1 were fused by seamless cloning to form the pWSPK_GPD1 plasmid for editing the GPD1 gene.

[0228] [Table 6]

[0229] 3. Construction of strains with PDC1 and GPD1 gene knockouts Fragments PDC1_1 and PDC1_2 and plasmid pWSPK_PDC1 were transferred simultaneously into SA101-2. A positive transformant was identified with primers PDC1_1F / PDC1_2R and named strain SA104 (genotype: SA101-2, ΔPDC1). After electrotransformation of pWSPK_GPD1 plasmid and fragments GPD1_1 and GPD1_2 into strain SA104, a positive transformant was obtained by screening on SD-URA culture medium and named strain SA105 (genotype: SA104, ΔGPD1).

[0230] Example 6: Overexpression of the SpMAE1 gene in the SA101-2 strain The SpMAE1 transport protein from Schizosaccharomyces pombe (Uniprot database search number: P50537) was expressed in the MCH4 locus of the CY902 genome, and the SpMAE1 gene was synthesized by Nanjing GenScript Biotech Co.,Ltd (SEQ ID NO:2) and optimized according to the codon selection of CY902. The promoter and terminator used were the promoter of the glyceraldehyde-3-phosphate dehydrogenase 3 gene TDH3 of CY902 itself (SEQ ID NO:19) and the terminator of the gene GAL2 encoding the galactose transport protein (SEQ ID NO:20), respectively. The specific construction method was as follows.

[0231] 1. Construction of donor DNA fragment for homologous recombination Using CY902 genomic DNA as a template, the upstream homology arm fragment 1 of the MCH4 gene (fragment 20) was amplified with primers 1_UP_MCH4_F and 1_UP_MCH4_R1 (see Table 7). The TDH3 gene promoter sequence of CY902 itself (fragment 21) was amplified with primer 2_P TDH3 _F and 2_P TDH3 The SpMAE1 coding sequence of Schizosaccharomyces pombe (fragment 22) was amplified with primers 3_SpMAE1_F and 3_SpMAE1_R (see Table 7) using a plasmid containing the SpMAE1 synthetic sequence as a template. The GAL2 gene terminator sequence of CY902 itself (fragment 23) was amplified with primers 4_T and 4_T using CY902 genomic DNA as a template. GAL2 _F and 4_T GAL2_R (see Table 7). Downstream homology arm fragment 1 of the MCH4 gene (fragment 24) was amplified with primers 5_DW_MCH4_F1 and 5_DW_MCH4_R (see Table 7). Upstream homology arm fragment 2 of the MCH4 gene (fragment 25) was amplified with primers 1_UP_MCH4_F and 1_UP_MCH4_R2 (see Table 7) using CY902 genomic DNA as a template. Downstream homology arm fragment 2 of the MCH4 gene (fragment 26) was amplified with primers 5_DW_MCH4_F2 and 5_DW_MCH4_R (see Table 7).

[0232] 2. Construction of plasmid for editing MCH4 of CY902 itself Using the pWSPK-Cas9 plasmid as a template, the 5'-end sequence of sgRNA (abbreviated as MCH4_sgRNA_1) was amplified with primers sgRNA-1F and MCH4_sgRNA-1R (see Table 7), and the 3'-end of this fragment contained a 20-nt protospacer specific for the Pichia kudria bzevii PkMCH4 gene. The pWSPK_backbone, sgRNA_2 and MCH4_sgRNA_1 were ligated using a seamless cloning kit to finally obtain a positive cloning plasmid named pWSPK_MCH4.

[0233] [Table 7]

[0234] 3. Construction of strains overexpressing the SpMAE1 gene The pWSPK_MCH4 plasmid and fragments 25 and 26 were transferred into SA101-2 strain according to the yeast electrotransformation method, and a positive transformant was screened and obtained, and named SA106-1 (genotype: SA101-2, ΔPkMCH4). The pWSPK_MCH4 plasmid and fragments 20-24 were electrotransformed into SA101-2 strain, and a positive transformant was screened and obtained, and named SA106-2 (genotype: SA101-2, PkMCH4::P PkTDH3 -ORF SpMAE1-T PkGAL2 ) and named it.

[0235] Example 7: Overexpression of PYC genes in the SA101-2 strain The Aspergillus oryzae derived PYC (AoPYC) gene (Uniprot database search number: Q2UGL1) (SEQ ID NO: 6) was overexpressed in the JEN2-1 locus, and the CY902's own PYC1 (PkPYC1) gene was used as a control (SEQ ID NO: 7). The promoter and terminator used were the TDH3 promoter (SEQ ID NO: 19) and the GAL2 terminator (SEQ ID NO: 20), respectively. The AoPYC gene was synthesized by Nanjing GenScript Biotech Co.,Ltd and optimized according to the codon selection of CY902 (SEQ ID NO: 6). The specific construction method was as follows:

[0236] 1. Construction of donor DNA fragment for homologous recombination Using CY902 genomic DNA as a template, the upstream homology arm fragment 1 of the JEN2-1 gene (fragment 27) was amplified with primers 1_UP_JEN2-1_F and 1_UP_JEN2-1_R1 (see Table 8). The PkPYC1 coding sequence of CY902 itself (fragment 28-1) was amplified with primers 3_PkPYC1_F and 3_PkPYC1_R (see Table 8). Using a plasmid containing the AoPYC synthetic sequence as a template, the AoPYC coding sequence from Aspergillus oryzae (fragment 28-2) was amplified with primers 3_AoPYC_F and 3_AoPYC_R (see Table 8). Using CY902 genomic DNA as a template, downstream homology arm fragment 1 (fragment 29) of the JEN2-1 gene was amplified with primers 5_DW_JEN2-1_F1 and 5_DW_JEN2-1_R (see Table 8). Using CY902 genomic DNA as a template, upstream homology arm fragment 2 (fragment 30) of the JEN2-1 gene was amplified with primers 1_UP_JEN2-1_F and 1_UP_JEN2-1_R2 (see Table 8). Downstream homology arm fragment 2 (fragment 31) of the JEN2-1 gene was amplified with primers 5_DW_JEN2-1_F2 and 5_DW_JEN2-1_R (see Table 8).

[0237] [Table 8]

[0238] 2. Construction of CRISPR / Cas9 plasmid for editing the JEN2-1 gene Using the pWSPK-Cas9 plasmid as a template, the 5'-end sequence of sgRNA (abbreviated as JEN2-1_sgRNA_1) was amplified with primers sgRNA-1F and JEN2-1_sgRNA-1R (see Table 8), and the 3'-end of this fragment contained a 20-nt protospacer specific to the JEN2-1 gene. The pWSPK_backbone and sgRNA_2 and JEN2-1_sgRNA_1 of Example 1 were ligated using a seamless cloning kit, finally obtaining a positive cloning plasmid named pWSPK_JEN2-1.

[0239] 3. Construction of strains overexpressing PYC genes The pWSPK_JEN2-1 plasmid and fragments 30 and 31 were electrotransformed into the SA101-2 strain, and positive transformants were screened and obtained, and named SA107-1 (genotype: SA101-2, ΔPkJEN2-1). The pWSPK_JEN2-1 plasmid and fragments 27, 21, 28, 23 and 29 were electrotransformed into the SA101-2 strain, and positive transformants were screened and obtained, and named SA107-2 (genotype: SA101-2, PkJEN2-1::P ... PkTDH3 -ORF PkPYC1 -T PkGAL2 ), SA107-3 (genotype: SA101-2, PkJEN2-1::P PkTDH3 -ORF AoPYC -T PkGAL2 ) and named it.

[0240] Example 8: Overexpression of the PkFUM1 gene in the SA101-2 strain The CY902 fumarase gene PkFUM1 (SEQ ID NO: 8) with the 5'-terminal mitochondrial localization peptide truncated was overexpressed in the PDC1 gene promoter locus of the SA101-2 strain. The promoter and terminator used were the TDH3 promoter (SEQ ID NO: 19) and the GAL2 terminator (SEQ ID NO: 20). The specific construction method was as follows.

[0241] 1. Construction of donor DNA fragment for homologous recombination Using CY902 genomic DNA as a template, the upstream homology arm fragment (fragment 32) of the PDC1 gene promoter of CY902 itself was amplified using primer 1_UP_P PDC1 _F and 1_UP_P PDC1The downstream homology arm fragment of the PDC1 gene promoter of CY902 itself (fragment 34) was amplified with primers 5_DW_P and 5_PkFUM1_R (see Table 9). The FUM1 coding sequence with the 5'-terminal mitochondrial localization peptide truncated (fragment 33) was amplified with primers 3_PkFUM1_F and 3_PkFUM1_R (see Table 9). PDC1 _F and 5_DW_P PDC1 _R (see Table 9).

[0242] 2. Construction of plasmid for editing the pDC1 gene promoter locus Using the pWSPK-Cas9 plasmid as a template, the 5'-terminal sequence of sgRNA (P PDC1 _sgRNA_1) with primers sgRNA-1F and P PDC1 When amplified with _sgRNA-1R (see Table 9), the 3' end of this fragment contained P PDC1 A 20-nt protospacer specific to the gene promoter was included. pWSPK_backbone, sgRNA_2 and P PDC1 _sgRNA_1 was ligated using a seamless cloning kit to create pWSPK_P PDC1 A positive cloning plasmid, designated as , was finally obtained.

[0243] [Table 9]

[0244] 3. Construction of a strain overexpressing the PkFUM1 gene pWSPK_P PDC1 The plasmid and fragments 32, 21, 33, 23 and 34 were transferred into the SA101-2 strain according to the yeast electrotransformation method, and positive transformants were screened to obtain the SA108 strain (genotype: SA101-2, P PkPDC1 ::P PkTDH3 -ORF PkFUM1 -T PkGAL2 ) and named it.

[0245] Example 9: Complementary expression of the PkURA3 gene in SA101 series strains The orotidine 5'-phosphate decarboxylase gene PkURA3 (SEQ ID NO: 117) was complemented in the dicarboxylate transport protein PkJEN2-2 locus of the SA101 series strain. The promoter and terminator used were the promoter (SEQ ID NO: 118) and terminator (SEQ ID NO: 119) of PkURA3 itself. The specific construction method was as follows.

[0246] 1. Construction of donor DNA fragment for homologous recombination Using CY902 genomic DNA as a template, the upstream homology arm fragment 1 (fragment 35) of the PkJEN2-2 gene of CY902 itself was amplified with primers 1_UP_JEN2-2_F and 1_UP_JEN2-2_R1 (see Table 10). The URA3 promoter, open reading frame and terminator sequence (fragment 36) were amplified with primers 2_PkURA3_F and 2_PkURA3_R (see Table 10). The downstream homology arm fragment 1 (fragment 37) of the PkJEN2-2 gene of CY902 itself was amplified with primers 3_DW_JEN2-2_F1 and 3_DW_JEN2-2_R (see Table 10). Using CY902 genomic DNA as a template, the upstream homology arm fragment 2 (fragment 38) of the PkJEN2-2 gene of CY902 itself was amplified with primers 1_UP_JEN2-2_F and 1_UP_JEN2-2_R2 (see Table 10). The downstream homology arm fragment 2 (fragment 39) of the PkJEN2-2 gene of CY902 itself was amplified with primers 3_DW_JEN2-2_F2 and 3_DW_JEN2-2_R (see Table 10).

[0247] 2. Construction of plasmids for editing the PkJEN2-2 gene site Using the pWSPK-Cas9 plasmid as a template, the 5'-end sequence of sgRNA (abbreviated as JEN2-2_sgRNA_1) was amplified with primers sgRNA-1F and JEN2-2_sgRNA-1R (see Table 10), and the 3'-end of this fragment contained a 20-nt protospacer specific for the PkJEN2-2 gene promoter. The pWSPK_backbone, sgRNA_2 and JEN2-2_sgRNA_1 were ligated using a seamless cloning kit, finally obtaining a positive cloning plasmid named pWSPK_JEN2-2.

[0248] [Table 10]

[0249] 3. Construction of Strains Carrying Complementary PkURA3 Genes The pWSPK_JEN2-2 plasmid and fragments 38 and 39 were transferred into SA101-1, SA101-2 and SA101-3 strains according to the yeast electrotransformation method, and positive transformants were screened and obtained, and named SA109-1 strain (genotype: SA101-1, ΔPkJEN2-2), SA109-2 strain (genotype: SA101-2, ΔPkJEN2-2) and SA109-3 strain (genotype: SA101-3, ΔPkJEN2-2), respectively. The pWSPK_JEN2-2 plasmid and fragments 35 to 37 were transferred into SA101-1, SA101-2 and SA101-3 strains according to the yeast electrotransformation method, and positive transformants were screened and obtained, and named SA109-4 strain (genotype: SA101-1, PkJEN2-2::P ... PkURA3 -ORF PkURA3 -T PkURA3 ), SA109-5 strain (genotype: SA101-2, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ) and SA109-6 strain (genotype: SA101-3, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ) and named it.

[0250] Example 10: Complementary expression of PkURA3 gene in SA102-SA108 series strains With reference to Example 9, PkURA3 was complemented at the PkJEN2-2 locus of the SA102 to SA108 strains to produce the SA110-1 strain (genotype: SA102-1, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), SA110-2 strain (genotype: SA102-2, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), SA110-3 strain (genotype: SA102-3, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), SA111-1 strain (genotype: SA103-1, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), SA111-2 strain (genotype: SA103-2, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), SA111-3 strain (genotype: SA103-3, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), SA111-4 strain (genotype: SA103-4, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), SA112 strain (genotype: SA104, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), SA113 strain (genotype: SA105, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), SA114-1 strain (genotype: SA106-1, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), SA114-2 strain (genotype: SA106-2, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3), SA115-1 strain (genotype: SA107-1, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), SA115-2 strain (genotype: SA107-2, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), SA115-3 strain (genotype: SA107-3, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), and SA116 strain (genotype: SA108, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ) was obtained.

[0251] Example 11: Evaluation of succinic acid production ability of SA101-SA116 series strains 1. Fermentation using neutralizing agents 30 mL of yeast mineral salts culture medium (5% w / v glucose, 30 g / L CaCO 3 ) was inoculated with the strains of the SA101 to SA116 series, and then fermented in a flask with shaking at 30°C and 250 rpm for 24 hours. The succinic acid titer was measured by HPLC.

[0252] [Table 11]

[0253] 2. Fermentation without neutralizing agents 30 mL of yeast mineral salts culture medium (5% w / v glucose, 0 g / L CaCO 3 ) was inoculated with the strains of the SA101 to SA116 series, and then fermented in a flask with shaking at 30°C and 250 rpm for 24 hours. The succinic acid titer was measured by HPLC.

[0254] [Table 12]

[0255] Example 12: Optimization of succinic acid producing strains Referring to Example 5, the PDC1 and GPD1 genes were knocked out in SA103-4 to obtain strain SA117 (genotype: SA103-4, ΔPDC1) and strain SA118 (genotype: SA117, ΔGPD1).

[0256] With reference to Example 6, the SpMAE1 gene was overexpressed in SA118 to produce SA119-1 strain (genotype: SA118, ΔPkMCH4) and SA119-2 strain (genotype: SA118, PkMCH4::P PkTDH3 -ORF SpMAE1 -T PkGAL2 ) was obtained.

[0257] With reference to Example 7, two sources of PYC were overexpressed in the SA119-2 strain to produce SA120-1 strain (genotype: SA119-2, ΔPkJEN2-1), SA120-2 strain (genotype: SA119-2, PkJEN2-1::P PkTDH3 -ORF PkPYC1 -T PkGAL2 ), and SA120-3 strain (genotype: SA119-2, PkJEN2-1::P PkTDH3 -ORF AoPYC -T PkGAL2 ) was obtained.

[0258] With reference to Example 8, the fumarase gene PkFUM1 with the 5'-terminal mitochondrial localization peptide truncated was overexpressed in SA120-3 to produce SA121 strain (genotype: SA120-3, P PkPDC1 ::P PkTDH3 -ORF PkFUM1 -T PkGAL2 ) was obtained.

[0259] With reference to Example 9, the orotidine 5'-phosphate decarboxylase gene PkURA3 was complemented to the SA121 strain to produce the SA122 strain (genotype: SA121, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ) was obtained.

[0260] With reference to Example 4, the TbFRD gene was overexpressed in SA102-3 to produce the SA123 strain (genotype: SA102-3, ADH1::ORF TbFRD ) was obtained.

[0261] Referring to Example 5, the PDC1 and GPD1 genes were knocked out in SA123 to obtain strain SA124 (genotype: SA123, ΔPDC1) and strain SA125 (genotype: SA124, ΔGPD1).

[0262] With reference to Example 6, the SpMAE1 gene was overexpressed in SA125 to produce SA126-1 strain (genotype: SA125, ΔPkMCH4) and SA126-2 strain (genotype: SA125, PkMCH4::P PkTDH3 -ORF SpMAE1 -T PkGAL2 ) was obtained.

[0263] With reference to Example 7, two sources of PYC were overexpressed in the SA126-2 strain to produce SA127-1 strain (genotype: SA126-2, ΔPkJEN2-1), SA127-2 strain (genotype: SA126-2, PkJEN2-1::P PkTDH3 -ORF PkPYC1 -T PkGAL2 ), and SA127-3 strain (genotype: SA126-2, PkJEN2-1::P PkTDH3 -ORF AoPYC -T PkGAL2 ) was obtained.

[0264] With reference to Example 8, the fumarase gene PkFUM1 with the 5'-terminal mitochondrial localization peptide truncated was overexpressed in SA127-3 to obtain SA128 strain (genotype: SA127-3, P PkPDC1 ::P PkTDH3 -ORF PkFUM1 -T PkGAL2 ) was obtained.

[0265] With reference to Example 9, the orotidine 5'-phosphate decarboxylase gene PkURA3 was complemented to the SA128 strain to produce the SA129 strain (genotype: SA128, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ) was obtained.

[0266] Example 13: Evaluation of succinic acid production ability of SA122 and SA129 strains The SA122 and SA129 strains were grown and fermented in 5 L tanks (yeast mineral salts culture medium, 12% w / v glucose), respectively. Without neutralizing agents, the 36-h succinic acid titers reached 96.08 g / L and 46.02 g / L, respectively, with yields of 0.89 g / g and 0.57 g / g, respectively.

[0267] Example 14: Overexpression of the SbMDH gene in Pichia kudriabzevii CICC32244ΔURA3 strain Referring to Example 1, the gene URA3 encoding orotidine 5'-phosphate decarboxylase of CICC32244 (purchased from China Center of Industrial Culture Collection) was knocked out to obtain the CICC32244ΔURA3 mutant.

[0268] The pWSPK_2365 plasmid and fragments 6 and 7 were transferred into the CICC32244ΔURA3 strain according to the yeast electrotransformation method, and a positive transformant was screened and obtained, and named the SA130-1 strain (genotype: CICC32244ΔURA3, ΔPk2365). The pWSPK_2365 plasmid and fragments 1-5 were transferred into the CICC32244ΔURA3 strain according to the yeast electrotransformation method, and a positive transformant was screened and obtained, and named the SA130-2 strain (genotype: CICC32244ΔURA3, Pk2365::P PkFBA1 -ORF SbMDH -T PkINO1 ) and named it.

[0269] Example 15: Complementary expression of the PkURA3 gene in SA130 series strains With reference to Example 9, PkURA3 was complemented at the PkJEN2-2 locus of the SA130 series strains to produce strain SA131-1 (genotype: SA130-1, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ), and strain SA131-2 (SA130-2, PkJEN2-2::P PkURA3 -ORF PkURA3 -T PkURA3 ) was obtained.

[0270] Example 16: Evaluation of succinic acid production ability of SA130 and SA131 series strains 1. Fermentation using neutralizing agents 30 mL of yeast mineral salts culture medium (5% w / v glucose, 30 g / L CaCO 3 ) was inoculated with the strains of the SA130 and SA131 series and fermented in a shaking flask at 30°C and 250 rpm for 24 hours. The succinic acid titer was measured by HPLC.

[0271] [Table 13] 2. Fermentation without neutralizing agents 30 mL of yeast mineral salts culture medium (5% w / v glucose, 0 g / L CaCO 3 ) was inoculated with the strains of the SA130 and SA131 series and fermented in a shaking flask at 30°C and 250 rpm for 24 hours. The succinic acid titer was measured by HPLC.

[0272] [Table 14] Example 17: Overexpression of SbMDH gene in Saccharomyces cerevisiae BY4742 strain Sorghum bicolor malate dehydrogenase SbMDH (SEQ ID NO: 1) was overexpressed at the orotidine 5'-phosphate decarboxylase gene ScURA3 (SEQ ID NO: 129) locus of Saccharomyces cerevisiae, and the strain overexpressing the ScURA3 gene served as a control. The overexpression of the SbMDH gene sequence was the same as above and optimized according to the codon preferences of CY902. The promoter and terminator used were the promoter of the glyceraldehyde 3-phosphate dehydrogenase-encoding gene ScTDH3 (SEQ ID NO: 130) and the terminator of the galactose permease gene ScGAL2 (SEQ ID NO: 131) of BY4742 itself, respectively. The promoter and terminator used for overexpression of the ScURA3 gene were the promoter (SEQ ID NO: 132) of the orotidine 5'-phosphate decarboxylase gene ScURA3 of BY4742 itself and the terminator (SEQ ID NO: 133) of the gene ScSED1 encoding a GPI cell wall glycoprotein, respectively. The specific construction method was as follows.

[0273] 1. Construction of donor DNA fragment for homologous recombination The genomic DNA of Saccharomyces cerevisiae S288c (purchased from ThermoFisher Scientific) was used as a template to amplify the ScURA3 upstream homology arm and open reading frame (ORF) sequence (fragment 40) with primers 1_UP_ScURA3_F and 1_ScURA3_R (see Table 15). The ScSED1 terminator sequence 1 (fragment 41) was amplified with primer 2_T ScSED1 _F and 2_T ScSED1 The ScTDH3 gene promoter sequence (fragment 42) was amplified with primer 3_P ScTDH3 _F and 3_P ScTDH3The SbMDH coding sequence from Sorghum bicolor (fragment 43) was amplified with primers 4_SbMDH_F and 4_SbMDH_R (see Table 15) using a plasmid containing the SbMDH synthetic sequence as a template. The ScGAL2 gene terminator sequence (fragment 44) was amplified with primers 5_T and 5_T using S288c genomic DNA as a template. ScGAL2 _F and 5_T ScGAL2 The downstream homology arm fragment 1 of the ScURA3 gene (fragment 45) was amplified with primers 6_DW_ScURA3_F1 and 6_DW_ScURA3_R (see Table 15). The ScSED1 terminator sequence 2 (fragment 46) was amplified with primers 2_T ScSED1 _F and 2_T ScSED1 The downstream homology arm fragment 2 of the ScURA3 gene (fragment 47) was amplified with primers 6_DW_ScURA3_F2 and 6_DW_ScURA3_R (see Table 15).

[0274] 2. Construction of Saccharomyces cerevisiae strains overexpressing SbMDH Fragments 40, 46 and 47 were mixed together and transferred into the BY4742 strain (purchased from ThermoFisher Scientific) according to the yeast electrotransformation method, and positive transformants were screened to obtain SA132-1 strain (genotype: BY4742, ScURA3::P ScURA3 -ORF ScURA3 -T ScSED1t Fragments 40 to 45 were mixed together and transferred into strain BY4742 according to the yeast electrotransformation method, and a positive transformant was screened to obtain strain SA132-2 (genotype: BY4742, ScURA3::P ScURA3 -ORF ScURA3 -T ScSED1t -P ScTDH3 -ORF SbMDH -T ScGAL2 ) and named it.

[0275] [Table 15]

[0276] Example 18: Evaluation of succinic acid production ability of SA132 series strains 1. Fermentation without neutralizing agents 30 mL of yeast mineral salts culture medium (5% w / v glucose, 0 g / L CaCO 3 ) was inoculated with the strains of the SA132 series and fermented in a shaking flask at 30°C and 250 rpm for 12 hours. The succinic acid titer was measured by HPLC.

[0277] [Table 16]

[0278] Example 19: Overexpression of SbMDH gene in Yarrowia lipolytica strain Po1g Because Yarrowia lipolytica has a very strong non-homologous end joining ability, we overexpressed the malate dehydrogenase gene SbMDH (SEQ ID NO: 1) from Sorghum bicolor and the screening marker β-isopropylmalate dehydrogenase (EC1.1.1.85) gene YlLEU2 (SEQ ID NO: 148) using random insertion into the Yarrowia lipolytica genome, and the Yarrowia lipolytica strain into which the overexpressed YlLEU2 gene was randomly inserted served as a control. The overexpression of the SbMDH gene sequence was the same as above and was optimized according to the codon selection of CY902. The promoter and terminator used were the promoter of the glyceraldehyde 3-phosphate dehydrogenase gene YlGAPDH (SEQ ID NO: 149) and the terminator of the 3-hydroxy-3-methylglutaryl coenzyme A reductase gene YlHMG1 (SEQ ID NO: 150) of Po1g itself, respectively. The promoter and terminator used for overexpression of the YlLEU2 gene were the promoter (SEQ ID NO: 151) of the β-isopropylmalate dehydrogenase gene YlLEU2 of Polg itself and the terminator (SEQ ID NO: 152) of the Saccharomyces cerevisiae cytochrome c subtype 1 gene ScCYC1, respectively. The specific construction method was as follows.

[0279] 1. Construction of donor DNA fragment for homologous recombination Yarrowia lipolytica W29 genomic DNA (GenBank: GCA_001761485.1) was used as a template, and the YlGAPDH gene promoter sequence (fragment 48) was amplified using primer 1_P YlGAPDH _F and 1_P YlGAPDH The SbMDH coding sequence from Sorghum bicolor (fragment 49) was amplified with primers 2_SbMDH_F and 2_SbMDH_R (see Table 17) using a plasmid containing the SbMDH synthetic sequence as a template. The YlHMG1 gene terminal sequence (fragment 50) was amplified with primers 3_T and 3_T using Yarrowia lipolytica W29 genomic DNA as a template. YlHMG1 _F and 3_T YlHMG1 _R (see Table 17). The YlLEU2 promoter and ORF sequence (fragment 51) were amplified with primer 4_P YlLEU2 The ScCYC1 terminator sequence (fragment 52) ​​was amplified with primers 5_T and 4_YlLEU2_R (see Table 17). ScCYC1 _F and 5_T ScCYC1 _R (see Table 17). Using fragments 48 to 52 as templates, an expression cassette overexpressing SbMDH and YlLEU2 (fragment 53) was amplified with primer 1_P YlGAPDH _F and 5_T ScCYC1 The expression cassette for overexpressing YlLEU2 (fragment 54) was amplified with primer 4_P using fragments 51 and 52 as templates. YlLEU2 _F and 5_T ScCYC1 Amplified with _R.

[0280] 2. Construction of Yarrowia lipolytica Strains Overexpressing SbMDH Fragment 54 was transferred into the Polg strain (purchased from Yeastern Biotechnology Development Co., Ltd.) according to the yeast electrotransformation method, and a positive transformant was obtained by screening, and the SA133-1 strain (genotype: Polg, genome: P YlLEU2 -ORF YlLEU2 -T ScCYC1t The fragment 53 was transferred into the Polg strain by the yeast electrotransformation method, and a positive transformant was screened to obtain strain SA133-2 (genotype: Polg, genome: P YlGAPDH -SbMDH-T YlHMG1t -P YlLEU2 -ORF YlLEU2 -T ScCYC1t ) and named it.

[0281] [Table 17]

[0282] Example 20: Evaluation of succinic acid production ability of SA133 series strains 1. Fermentation without neutralizing agents 30 mL of yeast mineral salts culture medium (5% w / v glucose, 0 g / L CaCO 3 ) was inoculated with the SA133 series strains and fermented in a shaking flask at 30°C and 250 rpm for 24 hours. The succinic acid titer was measured by HPLC.

[0283] [Table 18]

Claims

1. having NADPH-dependent malate dehydrogenase (EC 1.1.1.82) activity or enhanced activity; Optionally, the enzyme further has an activity or enhanced activity of at least one of: (i) a soluble fumarate reductase (EC 1.3.1.6), optionally with a 3'-terminal glyoxysomal localization peptide of said soluble fumarate reductase partially or completely truncated; (ii) a pyruvate carboxylase (EC 6.4.1.1); (iii) a fumarase (EC 4.2.1.2), optionally with a 5'-terminal mitochondrial localization peptide of said fumarase partially or completely truncated; and (iv) a succinate transport protein; Preferably, said NADPH-dependent malate dehydrogenase is derived from a plant, more preferably a C4 plant, more preferably from a plant of the family Poaceae, Cyperaceae, Asteraceae, Euphorbiaceae, Chenopodiaceae, Portulacaceae or Amaranthaceae, or from the genus Euglena or Thermobacillus, more preferably from Sorghum bicolor, Zea mays, Saccharum officinarum, Pisum sativum, Schisa aritinum, Spinacia oleracea, Euglena gracilis or Methanothermobacter thermoautotrophicus, More preferably, the NADPH-dependent malate dehydrogenase is an NADPH-dependent malate dehydrogenase derived from Sorghum bicolor; Preferably, the soluble fumarate reductase is derived from Saccharomyces cerevisiae, Trypanosoma brucei, Leishmania mexicana or Trypanosoma cruzi, more preferably from Trypanosoma brucei; Preferably, the succinate transport protein is selected from the group consisting of SpMAE1 protein, AnDCT-02 protein, EcDcuB protein and EcDcuC protein, more preferably SpMAE1 protein; Preferably, the pyruvate carboxylase is derived from Aspergillus oryzae or Pichia kudryabzevii, more preferably from Aspergillus oryzae. Genetically modified succinic acid producing yeast strain.

2. of reduced activity or inactivated (i) pyruvate decarboxylase (EC 4.1.1.43), and / or (ii) NAD-dependent glycerol 3-phosphate dehydrogenase (EC 1.1.1.8), and / or (iii) orotidine 5'-phosphate decarboxylase (EC 4.1.1.23), and / or (iv) a monocarboxylate permease, and / or (v) dicarboxylate transport protein, and / or (vi) alcohol dehydrogenase 1 (EC 1.1.1.1), and / or (vii) A bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase (EC 4.1.3.17 or 4.1.1.112) 2. The genetically modified succinic acid producing yeast strain of claim 1, further comprising:

3. (i) the overexpressed nucleic acid sequence encoding the NADPH-dependent malate dehydrogenase, preferably the nucleic acid sequence encoding the NADPH-dependent malate dehydrogenase, comprises a nucleotide sequence encoding an amino acid sequence having the sequence of SEQ ID NO: 1 or a degenerate sequence thereof or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having NADPH-dependent malate dehydrogenase activity; and / or (ii) the overexpressed nucleic acid sequence encoding the soluble fumarate reductase, preferably the nucleic acid sequence encoding the soluble fumarate reductase, comprises a nucleotide sequence encoding an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having soluble fumarate reductase activity; and / or (iii) the overexpressed nucleic acid sequence encoding the succinate transport protein, preferably the nucleic acid sequence encoding the succinate transport protein, comprises a nucleotide sequence encoding an amino acid sequence having the sequence of SEQ ID NO: 2 or a degenerate sequence thereof or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having succinate transport protein activity, and / or (iv) the overexpressed nucleic acid sequence encoding the pyruvate carboxylase, preferably the nucleic acid sequence encoding the pyruvate carboxylase, comprises a nucleotide sequence encoding an amino acid sequence having the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having pyruvate carboxylase activity; and / or (v) the overexpressed nucleic acid sequence encoding said fumarase, preferably said nucleic acid sequence encoding said fumarase, comprises a nucleotide sequence encoding an amino acid sequence having the sequence of SEQ ID NO: 8 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto, and having phosphoenolpyruvate carboxylase activity; and / or (vi) a knockout of the endogenous gene encoding pyruvate decarboxylase; and / or (vii) a knocked-out endogenous gene encoding an NAD-dependent glycerol 3-phosphate dehydrogenase; and / or (viii) a knocked-out endogenous gene encoding orotidine 5'-phosphate decarboxylase; and / or (ix) a knocked-out endogenous gene encoding a monocarboxylate permease; and / or (x) a knocked-out endogenous gene encoding a dicarboxylate transport protein, and / or (xi) a knocked-out endogenous gene encoding alcohol dehydrogenase 1; and / or (xii) a knocked-out endogenous gene encoding the bifunctional enzyme oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase; The genetically modified succinic acid producing yeast strain of claim 1 or 2, having the formula:

4. In the genetically modified succinic acid producing yeast strain, (a) a nucleic acid sequence encoding the NADPH-dependent malate dehydrogenase and the following nucleic acid sequence: a nucleic acid sequence encoding said soluble fumarate reductase, a nucleic acid sequence encoding the succinate transport protein; a nucleic acid sequence encoding said pyruvate carboxylase, and a nucleic acid sequence encoding said fumarase; and at least one of (b) the nucleic acid sequence encoding the NADPH-dependent malate dehydrogenase is overexpressed and the endogenous gene encoding pyruvate decarboxylase and / or the endogenous gene encoding NAD-dependent glycerol 3-phosphate dehydrogenase is knocked out; (c) the nucleic acid sequence encoding the NADPH-dependent malate dehydrogenase, the nucleic acid sequence encoding the pyruvate carboxylase, the nucleic acid sequence encoding the soluble fumarate reductase, and the nucleic acid sequence encoding the succinate transport protein are overexpressed, and the endogenous gene encoding the pyruvate decarboxylase and / or the endogenous gene encoding the NAD-dependent glycerol 3-phosphate dehydrogenase are knocked out; (d) the nucleic acid sequence encoding the NADPH-dependent malate dehydrogenase, the nucleic acid sequence encoding the pyruvate carboxylase, the nucleic acid sequence encoding the soluble fumarate reductase, the nucleic acid sequence encoding the fumarase, and the nucleic acid sequence encoding the succinate transport protein are overexpressed, and the endogenous gene encoding the pyruvate decarboxylase and / or the endogenous gene encoding the NAD-dependent glycerol 3-phosphate dehydrogenase are knocked out; Preferably, the nucleic acid sequence encoding the NADPH-dependent malate dehydrogenase is a nucleic acid sequence encoding the NADPH-dependent malate dehydrogenase of Sorghum bicolor, more preferably a nucleic acid sequence comprising the sequence of SEQ ID NO: 1 or a degenerate sequence thereof; Preferably, said nucleic acid sequence encoding said soluble fumarate reductase is a nucleic acid sequence encoding a soluble fumarate reductase derived from Saccharomyces cerevisiae, Trypanosoma brucei, Leishmania mexicana or Trypanosoma cruzi, more preferably a nucleic acid sequence comprising any one of the sequences of SEQ ID NOs: 3 to 5 or a degenerate sequence thereof; Preferably, the nucleic acid sequence encoding the succinate transport protein is a nucleic acid sequence encoding the SpMAE1 protein, more preferably a nucleic acid sequence comprising the sequence of SEQ ID NO: 2 or a degenerate sequence thereof; Preferably, the nucleic acid sequence encoding the pyruvate carboxylase encodes a pyruvate carboxylase derived from Aspergillus oryzae or Pichia kudryabzevi, more preferably comprising the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof. The genetically modified succinic acid producing yeast strain according to any one of claims 1 to 3.

5. The genetically modified succinic acid producing yeast strain according to any one of claims 1 to 4, wherein the succinic acid producing yeast strain is selected from the group consisting of Pichia, Rhodotorula, Saccharomyces, Yarrowia, Zygosaccharomyces, Torulopsis and Candida, preferably selected from the group consisting of Pichia, Saccharomyces and Yarrowia, more preferably Pichia kudriabzevi, Saccharomyces cerevisiae or Yarrowia lipolytica, for example Pichia kudriabzevi deposited at the Center for Ordinary Microorganisms of the China Microorganism Species Depository (CGMCC) under the deposit number CGMCC No. 20885.

6. 1. A method of constructing a genetically modified succinic acid producing yeast strain, comprising conferring or enhancing an activity of NADPH-dependent malate dehydrogenase (EC 1.1.1.82) to said strain, and optionally further comprising conferring or enhancing at least one of the following activities: (i) a soluble fumarate reductase activity, optionally wherein said soluble fumarate reductase is freely present in the cytoplasm, (ii) a pyruvate carboxylase (EC 6.4.1.1) activity, (iii) a fumarase (EC 4.2.1.2) activity, optionally wherein said fumarase is freely present in the cytoplasm, and (iv) a succinate transport protein activity; Preferably, the soluble fumarate reductase is derived from Saccharomyces cerevisiae, Trypanosoma brucei, Leishmania mexicana or Trypanosoma cruzi; Preferably, the succinate transport protein is selected from the group consisting of SpMAE1 protein, AnDCT-02 protein, EcDcuB protein and EcDcuC protein; Preferably, the pyruvate carboxylase is derived from Aspergillus oryzae or Pichia kudryabzevii, Preferably, said NADPH-dependent malate dehydrogenase is derived from a plant, more preferably a C4 plant, more preferably from a plant of the family Poaceae, Cyperaceae, Asteraceae, Euphorbiaceae, Chenopodiaceae, Portulacaceae or Amaranthaceae, or from the genus Euglena or Thermobacillus, more preferably from Sorghum bicolor, Zea mays, Saccharum officinarum, Pisum sativum, Schisa aritinum, Spinacia oleracea, Euglena gracilis or Methanothermobacter thermoautotrophicus, More preferably, the method wherein the NADPH-dependent malate dehydrogenase is Sorghum bicolor-derived NADPH-dependent malate dehydrogenase.

7. In the strain, (i) pyruvate decarboxylase (EC 4.1.1.43), and / or (ii) NAD-dependent glycerol 3-phosphate dehydrogenase (EC 1.1.1.8), and / or (iii) orotidine 5'-phosphate decarboxylase (EC 4.1.1.23), and / or (iv) a monocarboxylate permease, and / or (v) alcohol dehydrogenase 1 (EC 1.1.1.1), and / or (vi) a dicarboxylate transport protein, and / or (vii) A bifunctional enzyme of oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase (EC 4.1.3.17 or 4.1.1.112) The method of claim 6, further comprising attenuating or inactivating

8. In the succinic acid producing yeast strain, (i) overexpressing a nucleic acid sequence encoding said NADPH-dependent malate dehydrogenase, preferably comprising a nucleotide sequence encoding an amino acid sequence having the sequence of SEQ ID NO:1 or a degenerate sequence thereof or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto and having NADPH-dependent malate dehydrogenase activity; and / or (ii) overexpressing a nucleic acid sequence encoding said soluble fumarate reductase, preferably comprising a nucleotide sequence encoding an amino acid sequence having any one of SEQ ID NOs: 3 to 5 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto, and having soluble fumarate reductase activity; and / or (iii) overexpressing a nucleic acid sequence encoding said succinate transport protein, preferably comprising a nucleotide sequence encoding an amino acid sequence having the sequence of SEQ ID NO: 2 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto, and having succinate transport protein activity; and / or (iv) overexpressing said nucleic acid sequence encoding said pyruvate carboxylase, preferably comprising a nucleotide sequence encoding an amino acid sequence having the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto, and having pyruvate carboxylase activity; and / or (v) overexpressing a nucleic acid sequence encoding said fumarase, preferably comprising a nucleotide sequence encoding an amino acid sequence having the sequence of SEQ ID NO: 8 or a degenerate sequence thereof, or at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity thereto, and having phosphoenolpyruvate carboxylase activity; and / or (vi) knocking out the endogenous gene encoding pyruvate decarboxylase, and / or (vii) knocking out the endogenous gene encoding NAD-dependent glycerol 3-phosphate dehydrogenase, and / or (viii) knocking out the endogenous gene encoding orotidine 5'-phosphate decarboxylase, and / or (ix) knocking out an endogenous gene encoding a monocarboxylate permease, and / or (x) knocking out an endogenous gene encoding a dicarboxylate transport protein, and / or (xi) knocking out the endogenous gene encoding alcohol dehydrogenase 1, and / or (xii) knocking out the endogenous gene encoding the bifunctional enzyme oxaloacetate decarboxylase and 3-hydroxy-3-methylglutarate aldolase; The method of claim 6 or 7, comprising:

9. In the succinic acid producing yeast strain, (a) a nucleic acid sequence encoding the NADPH-dependent malate dehydrogenase and the following nucleic acid sequence: a nucleic acid sequence encoding said soluble fumarate reductase, a nucleic acid sequence encoding the succinate transport protein; a nucleic acid sequence encoding said pyruvate carboxylase, and a nucleic acid sequence encoding said fumarase; and overexpressing at least one of (b) overexpressing a nucleic acid sequence encoding said NADPH-dependent malate dehydrogenase and knocking out an endogenous gene encoding pyruvate decarboxylase and / or an endogenous gene encoding NAD-dependent glycerol 3-phosphate dehydrogenase; (c) overexpressing the nucleic acid sequence encoding the NADPH-dependent malate dehydrogenase, the nucleic acid sequence encoding the pyruvate carboxylase, the nucleic acid sequence encoding the soluble fumarate reductase, and the nucleic acid sequence encoding the succinate transport protein, and knocking out the endogenous gene encoding the pyruvate decarboxylase and / or the endogenous gene encoding the NAD-dependent glycerol 3-phosphate dehydrogenase; (d) overexpressing the nucleic acid sequence encoding the NADPH-dependent malate dehydrogenase, the nucleic acid sequence encoding the pyruvate carboxylase, the nucleic acid sequence encoding the soluble fumarate reductase, the nucleic acid sequence encoding the fumarase, and the nucleic acid sequence encoding the succinate transport protein, and knocking out the endogenous gene encoding the pyruvate decarboxylase and / or the endogenous gene encoding the NAD-dependent glycerol 3-phosphate dehydrogenase; Preferably, the nucleic acid sequence encoding the NADPH-dependent malate dehydrogenase is a nucleic acid sequence encoding an NADPH-dependent malate dehydrogenase derived from Sorghum bicolor, more preferably comprising the sequence of SEQ ID NO: 1 or a degenerate sequence thereof; Preferably, said nucleic acid sequence encoding said soluble fumarate reductase is a nucleic acid sequence encoding a soluble fumarate reductase from Saccharomyces cerevisiae, Trypanosoma brucei, Leishmania mexicana or Trypanosoma cruzi, more preferably comprising any one of the sequences SEQ ID NOs: 3 to 5 or a degenerate sequence thereof; Preferably, said nucleic acid sequence encoding said succinate transport protein is a nucleic acid sequence encoding the SpMAE1 protein, more preferably comprising the sequence of SEQ ID NO: 2 or a degenerate sequence thereof; Preferably, the nucleic acid sequence encoding the pyruvate carboxylase encodes a pyruvate carboxylase derived from Aspergillus oryzae or Pichia kudryabzevi, more preferably comprising the sequence of SEQ ID NO: 6 or 7 or a degenerate sequence thereof. The method according to any one of claims 6 to 8.

10. The method according to any one of claims 6 to 9, wherein the succinic acid producing yeast strain is selected from the group consisting of Pichia, Rhodotorula, Saccharomyces, Yarrowia, Zygosaccharomyces, Torulopsis and Candida, preferably selected from the group consisting of Pichia, Saccharomyces and Yarrowia, more preferably Pichia kudriabzevi, Saccharomyces cerevisiae or Yarrowia lipolytica, such as Pichia kudriabzevi deposited at the Center for Ordinary Microorganisms of the China Microorganism Species Depository (CGMCC) under the deposit number CGMCC No. 20885.

11. A method for producing succinic acid, comprising culturing a genetically modified succinic acid-producing yeast strain according to any one of claims 1 to 5 or a genetically modified succinic acid-producing yeast strain prepared by the method according to any one of claims 6 to 10, preferably at a pH < 3.5, more preferably in the range of pH 1.5 to 3.5 and / or with no or low addition of neutralizing agent, and optionally isolating and purifying the produced succinic acid.

12. Use of the genetically modified succinic acid producing yeast strain according to any one of claims 1 to 5 or prepared by the method according to any one of claims 6 to 10 in the production of succinic acid, preferably at a pH < 3.5, more preferably in the pH range of 1.5 to 3.5 and / or with no or low addition of neutralizing agent.

Citation Information

Patent Citations

  • Yeast Cells Having NADP(H)-Dependent Reductive TCA Pathway from Pyruvate to Succinate

    US20150176038A1